header logo image


Page 21«..10..20212223..30..»

Archive for the ‘Molecular Genetics’ Category

Global Molecular Diagnostic Product Market Analysis And Forecast To 2026 By Recent Trends, Developments In Manufacturing Technology And Regional…

Tuesday, February 25th, 2020

Reportspedia.com in its latest market intelligence study, finds that the Global Molecular Diagnostic Product Market registered a value of ~US$ xx Mn/Bn in 2019 and is observed to grow at CAGR of xx% during the estimative period 2020-2026. In terms of product type, segments holds the significant share, in terms of end use. All the consumption trends and adoption patterns of the Molecular Diagnostic Product are covered in the report.

Download Exclusive Sample of Molecular Diagnostic Product Markets Premium Report at: https://www.reportspedia.com/report/life-sciences/global-molecular-diagnostic-product-market-report-2019,-competitive-landscape,-trends-and-opportunities/29662 #request_sample

Key Players:

SiemensBiotestIlluminaBioMerieuxAbbottTecan GroupFujirebioGrifolsCepheidKreatech/LeicaAffymetrixBiokitLi-Cor BiosciencesSierra MolecularOrtho-Clinical DiagnosticsElitech GroupApplied Gene TechnologiesMyriad GeneticsRocheTakara BioDiadexusBio-RadEnzoProteome SciencesShimadzuPerkin Elmer/CaliperAgilent TechnologiesMonogram Biosciences/LabCorpSequenomDecode GeneticsExact SciencesEikenScienionQiagenBecton DickinsonHologic/Gen-ProbeCellMark Forensics/LabCorpThermo FisherArca BiopharmaBeckman Coulter/Danaher

The Molecular Diagnostic Product industry report offers in-depth analysis and insights into developments impacting businesses and enterprises on a global & regional level. A detailed breakdown of key trends, drivers, restraints, and opportunities influencing revenue growth is presented in this research report. This study focuses on the global Molecular Diagnostic Product market by share, volume, value, and regional appearance along with the types and applications. The market is divided into the below points:

Market by Type/Products:

Type 1Type 2Type 3

Market by Application/End-Use:

Application 1Application 2Application 3

Enquire or share your questions if any before the purchasing this report @ https://www.reportspedia.com/report/life-sciences/global-molecular-diagnostic-product-market-report-2019,-competitive-landscape,-trends-and-opportunities/29662 #inquiry_before_buying

The geographical analysis covers the following regions:

The Molecular Diagnostic Product market research answers important questions, including the following:

The Molecular Diagnostic Product market research serves a platter of the following information:

In-depth analysis of the drivers, restraints, opportunities and trends influencing the growth of the global Molecular Diagnostic Product market. Critical breakdown of the Molecular Diagnostic Product market as per product type, and end use industry. Exhaustive understanding of the strengths, weaknesses, opportunities and threats of various Molecular Diagnostic Product market players. Precise year-on-year growth of the global Molecular Diagnostic Product market in terms of value and volume.

Key questions answered by this report include:

Table of contents:

Click here to access Detailed Table of Contents @ https://www.reportspedia.com/report/life-sciences/global-molecular-diagnostic-product-market-report-2019,-competitive-landscape,-trends-and-opportunities/29662 #table_of_contents

Thanks A Million For Reading This Article!!!

More here:
Global Molecular Diagnostic Product Market Analysis And Forecast To 2026 By Recent Trends, Developments In Manufacturing Technology And Regional...

Read More...

Boyd named chief scientific officer at Cancer Institute – News – The Island Now

Saturday, February 22nd, 2020

Jeff Boyd will be serving as vice president and chief scientific officer and director of the Center for Genomic Medicine at Northwell Health Systems Cancer Institute in Lake Success. He will also hold an appointment as professor and member of the Cold Spring Harbor Laboratory Cancer Center.

Boyd, who began in his position on Feb. 10, was working at the Miami Cancer Institute when he received the offer from Northwell.

It sounded like a great opportunity, Boyd said. Part of it involved being director of the Center for Genomic Medicine, being chief of science for the Cancer Institute, working at the Cold Spring Harbor lab, strengthening that relationship, providing them access to oncologists here, as well as tissue specimens and such that they need in a cancer research lab.

Part of the doctors job will involve the creation of a clinical laboratory and molecular diagnostic lab certified by the Department of Health, where researchers can obtain tumor specimens from cancer patients, isolate DNA and use a state-of-the-art technology known as next-generation DNA sequencing to define genetic architecture of a specific tumor in an individual.

Every breast cancer is different, liver cancer is different, colon cancer is different by the person, Boyd said.

The institute is also looking into the mutations that cause normal cells to turn cancerous, matching certain mutations to specific drugs in a way that Boyd likens to a lock and key.

Were at a point now in our understanding of cancer genetics in drugs being developed that we can match specific drugs precision cancer medicine match a drug to a mutation in that patients tumor, and it stops what its doing to make a normal cell a cancer cell, Boyd said. Thats whats looking to replace chemotherapy. Most of the therapy is nontoxic, it would describe mutations in tumor and any drugs available for that mutation, and thats the future of cancer treatment.

Another operational unit has to do with banking cancer specimens and fluids like blood and urine from cancer patients, where a state-of-the-art specimen vial depository that will take samples ranging from tumor tissue, blood, and urine, all connected to electronic med record.

The days of taking small bits of tumor or vials of blood and putting them in freezer are gone, Dr. Boyd said.

These specimens will be available to any researchers in the Northwell system, as well as those in the Cold Spring Harbor laboratory.

Our colleagues at Cold Spring Harbor are important to the success of our work, Dr. Boyd said.

Dr. Richard Barakat, physician-in-chief and director of the Northwell Health Cancer Institute and senior vice president of cancer services at Northwell Health, had worked with Dr. Boyd at Memorial Sloan Kettering Cancer Center.

Genomics has become an important piece to helping us understand the genetic roots of the various forms of cancer, which is why it has become an important area of investment for Northwell Health, Barakat said. We are extremely fortunate to have such an esteemed cancer researcher and internationally-known genomics expert such as Boyd to join the Cancer Institutes leadership team.

Boyd has over 30 years of cancer research experience, most recently serving on the executive leadership team of the Miami Cancer Institute at Baptist Health South Florida as associate deputy director of translational research and genomic medicine.

He also served as a professor and chair of the department of human and molecular genetics, professor of obstetrics and gynecology, and associate dean for basic research and graduate programs at the Herbert Wertheim College of Medicine at Florida International University.

Prior to joining the Miami Cancer Institute in 2015, Dr. Boyd held senior leadership positions at prominent cancer centers across the country, serving as the first executive officer of the Cancer Genome Institute at the Fox Chase Center in Philadelphia, Penn.

He also held numerous senior positions at Memorial Sloan-Kettering Cancer Center and served as a faculty member at the University of Pennsylvania and the National Institutes of Health.

Boyd says he and his wife are in the process of moving and hope to live in Lloyd Harbor, close to the Cold Spring Harbor laboratories.

I like to build things, Dr. Boyd said. Ive been in this cancer research and clinical care space for decades, and there is unparalleled opportunity here.

Read the rest here:
Boyd named chief scientific officer at Cancer Institute - News - The Island Now

Read More...

Columbia Pediatrics Researchers Receive Seed Funding for Innovative Research – Columbia University Irving Medical Center

Saturday, February 22nd, 2020

Recipients of INF awards, from left, areSumeet Banker, Jennifer Woo-Baidal, Andrew Geneslaw, Julia Wynn, and Rebecca Hough. Not pictured: Michael DiLorenzo. (Photo: Charles Manley)

Six Columbia pediatrics researchers were awarded start-up funding from the Department of Pediatrics through a new Innovation Nucleation Fund. The recipients, announced during a department faculty meeting on Feb. 13, areSumeet Banker, MD, MPH,Michael DiLorenzo, MD, Julia Wynn, MS,Rebecca Hough, MD, PhD,Jennifer Woo-Baidal, MD, MPH, andAndrew Geneslaw, MD.

The fund wasestablished this year with contributions to the Department of Pediatrics from private donorsand is designed to bring a venture capital approach to supporting new research in childrens health.

The Innovation Nucleation Fund will allow our talented faculty the freedom to pursue innovative, bold ideas in research that could lead to the next major breakthrough in childrens health, saysJordan S. Orange, MD, PhD, the Reuben S. Carpentier Professor and Chair of the Department of Pediatrics at Columbia University Vagelos College of Physicians and Surgeons.

Awards of $10,000 to $50,000 were given to faculty whose projects demonstrated an ability to advance the departments mission of engaging in advocacy, clinical work, education, and basic or clinical translational research.

Advocacy

Sumeet Banker, MD, MPH,assistant professor of pediatrics in child and adolescent health, will study how to improve disparities in care and communication for children and families with limited proficiency in English.

Clinical Program

Michael DiLorenzo, MD,assistant professor of pediatrics in pediatric cardiology, will investigate the use of transcatheter-based imaging to treat lung problems caused by the accumulation of lymphatic fluid in children with congenital heart defects.

Education

Julia Wynn, MS, associate professor of genetic counseling in molecular genetics, will develop an interactive video educational tool to increase participation in pediatric genomics studies. Co-investigators on the project are Priyanka Ahimaz, MS, assistant professor of genetic counseling; Ilana Chilton, MS, lecturer in genetic counseling; Emily Griffin, MS, lecturer in genetic counseling; and Rebecca Hernan, MS, genetic counselor.

Basic/Translational Research

Rebecca Hough, MD, PhD,assistant professor of pediatrics in pediatric critical care medicine, will use imaging of live mouse lungs to better understand cell-to-cell communication underlying pediatric acute respiratory distress syndrome, with the goal of developing targeted therapies for the condition.

Clinical/Translational Research

Jennifer Woo-Baidal, MD, MPH, assistant professor of pediatrics in pediatric gastroenterology, hepatology, and nutrition, with co-investigator Dodi Meyer, MD, professor of pediatrics, will evaluate the implementation of Food FARMacia, a novel, clinically based food assistance program to prevent childhood obesity by tackling food insecurity in families with children under age 5.

Faculty INF Award

Andy Geneslaw, MD,instructor in pediatrics in pediatric critical care medicine, will use mobile technology to understand the neurodevelopment effect of severe respiratory failure in infants and toddlers.

A total of 25 proposals were submittedfor consideration by five senior faculty from the Department of Pediatrics.The application process was extremely competitive, and we received many superb proposals, says Orange. We look forward to seeing the impact of these brilliant researchers and their efforts in the near future.

Continue reading here:
Columbia Pediatrics Researchers Receive Seed Funding for Innovative Research - Columbia University Irving Medical Center

Read More...

Tackling Alzheimer’s and dementia in New Mexico – KUNM

Saturday, February 22nd, 2020

University Showcase 2/21 8a: Alzheimers and dementia represent a growing crisis around the world and New Mexico faces many challenges in addressing these illnesses.

On this episode we highlight a conference organized by the Alzheimer's Foundation of America coming to the University of New Mexico on February 25.

It is open to the public and no tickets are required, but participants can register here.

We also talk with Dr. Gary Rosenberg, founder of the UNM Memory & Aging Center.

The center opened in 2016 and focuses on advancing research on dementia and helping expand care around the state.

And we check in one with Nicole Maphis, Ph.D candidate in UNMs Biomedical Sciences Graduate Program, who is working on a vaccine for Alzheimers with Kiran Bhaskar, an associate professor in UNMs Department of Molecular Genetics & Microbiology, and Bryce Chackerian, Professor and Vice Chair, Molecular Genetics and Microbiology. Find the previous interview we did with these researchers here.

Guests:

Go here to see the original:
Tackling Alzheimer's and dementia in New Mexico - KUNM

Read More...

Shaping the future: Microbiologist’s career inspired by influential teacher – MSUToday

Saturday, February 22nd, 2020

Feb. 19, 2020

A Michigan State University scientist is determined to increase the number of women and girls going into STEM fields. Kayla Conner is a doctoral candidate in theDepartment of Microbiology and Molecular Geneticswho says she wouldnt be the student she is today if it werent for her high school chemistry teacher, Ms. Hardin.

Conner is part of MSUsBroadening Experiences in Scientific Training, an experimental program dedicated to empowering graduate student trainees to develop professional skills and experiences. Recently, reporters with WKAR News sat down with some of the BEST students to learn more about their inspiring life stories. Listen to the audio clip to hear Conners story in her own words and those of Hardin.

Conner is currently studying what happens to the placenta when a woman gets an infection during pregnancy and what that could mean for the fetus. Shes researching possible ways to stop some of the negative consequences that happen because of infection.

If a woman gets infected with any sort of ailment during pregnancy, whether it be the cold or the flu, it causes inflammation in the mother, says Conner. And that can lead to downstream effects, whether that is stillbirth, preterm labor, birth defects or even ailments later in life.

Conner was raised in Maynardville, Tennessee, and attended a small high school where she found the atmosphere to be less than encouraging and lacking resources for students who wanted to pursue higher education.

A lot of people have the mentality, Im from here so, therefore, I cant, and its really sad, she says. I really dont want people to have that mentality because even though you are from there you can do wonderful things. I dont think I would have had that drive without Ms. Hardin.

Conner looked up to her chemistry teacher and found encouragement to continue her studies.

She told me how well I was doing even when I felt like I wasnt, says Conner. I thought, Man, you know if she thinks I can do it, then maybe I can.

Hardin says that Conner gives her too much credit.

She has a scientific mind and shes curious, says Hardin. It was obvious to me. She had a natural talent for it. As a teacher, I encourage all my students, especially girls, to not look at science and math as something that boys do. You work at it. You keep plugging away and you can do it too.

For Conner, having women who have helped support her has been extremely important. Ive had women who told me that I can and who have helped me in every way they possibly can, she says. I think its important to give back and be that person for someone else. I go to the Girl Scout troops. I have a little outreach program where I do some hands-on activities and I give a talk. Its a fun time.

Only about 24 percent of the STEM workforce is made up of women. There have been studies that have shown that girls in lower education elementary and middle school show the same interest in STEM courses and enroll in courses at the same rates as their male student counterparts, but once it reaches the level of higher education, women do not seek out STEM courses as frequently as men do.

Conner recognizes the disconnect that is happening and strives to inspire talented women to pursue STEM careers.

Its not a mans game, Conner says. It is absolutely a womans game as well. We can be awesome scientists and be awesome mothers, friends and daughters and be whatever we want to be.

MSU BEST seeks to enhance trainees abilities to develop the confidence and competencies useful in navigating and choosing from diverse career opportunities.Learn more about becoming part of the BEST community.

Photos and video by Alec Gerstenberger.

See original here:
Shaping the future: Microbiologist's career inspired by influential teacher - MSUToday

Read More...

Home is where the heart lies: the amazing story of Chopin’s heart – The First News

Saturday, February 22nd, 2020

Bolesaw Bierut, the communist leader, hands over the casket containing Chopin's heart to Mayor of Warsaw Stanisaw Towiki in 1945. Public domain

When Chopin died in France at the early age of thirty-nine his famous deathbed wish was that his heart should be cut out from his body and sent to Poland.

Terrified of waking up in his own coffin, he said to his sister Ludwika, Swear to make them cut me open, so that I wont be buried alive.

This final morbid request set in motion an astonishing series of events connected with his heart that have lasted over 170 years.

They have involved his heart being smuggled into Tsarist-controlled Poland in a jar of cognac, lying for years in a junk yard, being seized, or perhaps saved, by the Germans during the Warsaw Uprising and finally being the subject of intriguing scientific analysis.

It was this last chapter that caught the attention of the world a few years ago, when Chopins heart was taken out of its casket from a pillar in the Holy Cross Church in Warsaw for the first time since October 1945.

It is common to hear in Poland that Chopin died of a broken heart that longed for its homeland. The real reason for his death, though, was widely attributed to tuberculosis. Yet, there have been doubts about the real cause for more than 170 years.

Chopin pictured in 1849. The composer was plagued by ill health for most of his life.Public domain

Chopin was sickly for most of his life. At the age of 28, he weighed just 45 kg and was diagnosed with tuberculosis, which was treated with fasting and drawing blood.

He often suffered from respiratory infections and coughed for most of his life. Throughout his last 10 years he took opium.

The report prepared by doctors upon his death no longer exists. However, accounts say that the cause of death was given as lung and laryngeal tuberculosis. Over the years, other hypotheses appeared, including cystic fibrosis.

Scientists thought that if they could examine his heart, they could finally determine the cause of his death.

After warnings that the alcohol in the jar containing the organ might have evaporated after 170 years, they finally got their chance when church bosses agreed to open the casket.

When a carefully selected conclave of churchmen and scientists met in secret late one April night in 2014 to open the casket, what they found was an enlarged and floppy heart, still submerged in an amber-brown liquid. This was most likely cognac, commonly used for tissue preservation in the 19th century.

Chopin's heart arriving in Warsaw in 1945.NAC

The researchers saw that the heart was covered with a fine coating of white fibrous materials. Small lesions were visible, the tell-tale symptoms of serious complications of tuberculosis.

The researchers concluded the musician had suffered from pericarditis, a rare complication of chronic tuberculosis. The diagnosis was published in the American Journal of Medicine at the end of 2017.

One of the authors, Professor Micha Witt, head of the Department of Molecular and Clinical Genetics of the Institute of Human Genetics of the Polish Academy of Sciences in Pozna, said: We didnt open the jar [] But from the state of the heart we can say, with high probability, that Chopin suffered from tuberculosis while the complication pericarditis was probably the immediate cause of his death.

The heart in a hermetically sealed crystal jar 16 centimetres high and 12 centimetres in diameter. The preserving liquid had lost at most half a centimetre.

The jar was located in a wooden box lined with lead panels. They did not open the jar. Instead, after a thorough visual examination, they strengthened the seal with bees wax.

One thing that they noticed was that the heart had suffered slight damage, probably from being buffeted on the journey from Paris to Warsaw.

An examination of the heart in 2014 came to the conclusion that Chopin had died from complications caused by TB.hopin's heart I should credit all those guys? Micha Witt, Artur Szklener, Wojciech Marchwica, Tadeusz Dobosz

The journey is believed to have taken place in 1850. At the time Poland was a constituent part of the Russian empire. Chopin was regarded as a national hero, so to avoid difficulties with the Tsarist authorities Chopins sister Ludwika decided to smuggle the heart into Warsaw. Legend says that she hid the jar with his heart under her skirt.

It was Chopin's wish to be laid to rest with his family in Powzki cemetery in Warsaw. However, as only his heart came back to the country, the choice was made to give it to the Holy Cross Church.

This was where all the family celebrations had been held, it was the Chopin family's parish church and it was the most important church in Warsaw.

Unfortunately, the church did not want the composers heart. His relationship with the progressive writer George Sand, who changed lovers like pairs of gloves, was deemed a scandal by the church hierarchy.

The heart of one of the worlds greatest ever composers was therefore dumped in part of the crypt where broken odds and ends were kept, in effect a junkyard.

It was probably thanks to this that it survived the plunder of the church by Russians soldiers during the 1863 January Uprising. In 1880, and epitaph was finally ordered. However in the intervening years, people had forgotten exactly where the heart was.

The current resting place of the heart in the Holy Cross Church.Kalbar/TFN

Eventually, a local journalist tracked it down to the crypt and the heart was moved to the main church with great honour.

His heart stayed there until the Warsaw Uprising in 1944 when it faced its greatest danger. But what exactly happened to Chopins heart during that turbulent time remains a mystery.

According to the wartime account of Father Alojzy Niedziela, a young priest at the Holy Cross Church, a German chaplain entered the church in early August and said that eventually the fighting would engulf the church. He asked therefore that Chopins heart be removed for its safekeeping.

There also exists a German newsreel film dated September 9, 1944 showing SS General Erich von dem Bach-Zelewski, accompanied by a unit standing to attention, giving the casket with Chopin's heart to Archbishop Antoni Szlagowski.

The Archbishop is said to have taken the heart to Milanwek and hidden it inside a piano until October 17, 1945, when it returned to Warsaw.

Some stories claim that a German priest may have removed the heart from the church during the war, thus saving it from destruction.Leszek Szymaski/PAP

However, Home Army reports say that the heart was in their possession when they seized the church around August 23, and that it only fell into German hands when they regained control of the church a few days later.

Chopin experts have not been able to reconcile the conflicting accounts to this day.

The heart finally came back to the Holy Cross Church on the anniversary of the composers death on October 17, 1945.

After all this turbulence, it looks likely that Chopins heart can now rest peacefully until the next scheduled viewing in 50 years.

However, some scientists are keen to open it and carry out DNA tests. Professor Witt opposes this idea though.

Genetic testing would require the jar to be opened, which could expose the preparation to serious damage as the atmosphere inside can change dramatically. This can have a very bad effect on what is inside, he said.

Read more here:
Home is where the heart lies: the amazing story of Chopin's heart - The First News

Read More...

Kallyope Inc. Appoints Peter Hecht to Board of Directors – BioSpace

Saturday, February 22nd, 2020

NEW YORK, Feb. 20, 2020 /PRNewswire/ -- Kallyope Inc., a leading biotechnology company focused on identifying and pursuing therapeutic opportunities involving the gut-brain axis, today announced that Peter Hecht, Ph.D., CEO of Cyclerion Therapeutics, has been appointed to the company's Board of Directors.

Prior to joining Cyclerion in 2019, Peter was co-founder and CEO of Ironwood Pharmaceuticals from 1998 to 2019. Under his leadership, Ironwood grew into a fully integrated research, development and commercial organization with more than 700 employees. During his tenure the company discovered, developed and commercialized LINZESS (linaclotide) globally for irritable bowel syndrome with constipation and chronic constipation. In 2019, Peter led the tax-free separation of Ironwood's non-gastrointestinal (GI) assets and R&D team into Cyclerion, enabling Ironwood to be a profitable GI therapeutics-focused leader. After completion of the spin-off, Hecht joined Cyclerion as its first CEO. He holds a Ph.D. in molecular biology from the University of California at Berkeley and was a post-doctoral research fellow at the Whitehead Institute.

"It is an exciting time to join Kallyope," said Hecht. "Their unique platform of integrated technologies has led to a new understanding of gut-brain circuits that has, in turn, resulted in the discovery of novel approaches to diseases of high unmet need in multiple therapeutic areas. I look forward to working with the team as the company begins to advance its portfolio of programs towards the clinic."

"We are delighted to welcome Peter to our Board of Directors at this pivotal time," said Nancy Thornberry, CEO of Kallyope. "As we progress our lead programs and expand our pipeline and novel platform, Peter's experience in building innovation-driven biotech startups into mature biopharmaceutical companies will be invaluable for us."

About Kallyope Inc.

Kallyope, headquartered at the Alexandria Centerfor Life Science in New York City, is a biotechnology company dedicated to unlocking the therapeutic potential of the gut-brain axis. The company's cross-disciplinary team integrates advanced technologies in sequencing, bioinformatics, neural imaging, cellular and molecular biology, and human genetics to provide an understanding of gut-brain biology that leads to transformational therapeutics to improve human health. The company's founders are Charles Zuker, Ph.D., Lasker Award winner Tom Maniatis, Ph.D., and Nobel laureate Richard Axel, M.D. For more information visitwww.kallyope.com.

Contact

Danielle Cantey(202) 337-0808dcantey@gpg.com

Morgan Warners(202) 337-0808mwarners@gpg.com

View original content to download multimedia:http://www.prnewswire.com/news-releases/kallyope-inc-appoints-peter-hecht-to-board-of-directors-301008114.html

SOURCE Kallyope Inc.

See the rest here:
Kallyope Inc. Appoints Peter Hecht to Board of Directors - BioSpace

Read More...

U of T and Sunnybrook virologists work on tools to combat coronavirus outbreak – News@UofT

Saturday, February 22nd, 2020

In order to contain a virus, its important to know exactly what youre dealing with and the COVID-19 coronavirus is no different.

One of the key tools to try to contain or limit transmission of infectious diseases is case identification, saysSamira Mubareka, a virologist in the University of Torontos Faculty of Medicine and at Sunnybrook Health Sciences Centre.

If you identify cases, then you can contain them. If you miss them, then you dont.

Mubareka and her colleagueRobert Kozak, both in U of Ts department of laboratory medicine and pathobiology, are part of a local working group of scientists who are researching the novel coronavirus outbreak and are developing a suite of tools to control it.

One of their current projects involves using the latest in whole-genome sequencing technology to help hospitals characterize the virus more quickly. Their work may help to track the viruss evolution and trace its spread.

If the viruss genome was a book, were going to figure out its entire story, Kozak says.

Mubareka and Kozak collected specimens of the coronavirus from the first confirmed case in Canada, an adult male who was treated and eventually discharged from Sunnybrook after returning from Wuhan, China the epicentre of the outbreak. Two more cases in Ontario have since been confirmed: the original patients wife, who accompanied him to China, and a woman in her 20s in London, Ont. who had also traveled to Wuhan.

Worldwide, there are more than 73,300 confirmed cases ofCOVID-19 as of Feb. 18. More than 1,800 have died.

Robert Kozak, pictured here in the lab, andSamira Mubareka say their teams work will enable front-line hospital staff to run a test on-site, helping to identify and triage patients more efficiently (photo by Nick Iwanyshyn)

In Canada, where there are so far seven confirmed cases, health authorities say the risk remains low. But Mubareka and Kozak are preparing for any possible scenario.

You put a smoke alarm in your house even if you hope theres no fire, says Kozak, who previously worked at the National Microbiology Laboratory in Winnipeg on Ebola and Zika.

Part of the teams work involves developing a test that will speed up the characterization of the virus. Currently, patient samples in Ontario are sent from local hospitals by courier to the Public Health Ontario lab in downtown Toronto for testing, and to the national lab in Winnipeg for confirmation.

The process can take a few days, depending on the hospitals distance from the labs and test volumes.

Mubareka and Kozak say their teams work in collaboration with McMaster University and infectious disease expert Allison McGeer of U of Ts Dalla Lana School of Public Health, Faculty of Medicine and Mount Sinai Hospital will enable front-line hospital staff to run a test on-site, helping to identify and triage patients more efficiently. The test involves using swabs from a patients nose and throat to do genomic testing to sequence the virus.

If theyre negative, you can take them [the patients] out of precautions and maybe even send them home, Kozak says. If theyre positive, then you can again take the appropriate precautions to isolate them and do everything else that needs to be done.

The researchers hope they can adapt the approach for mini-sequencers the size of a cell phone, so it can be used more widely.

Vivek Goel,U of Ts vice-president, research and innovation, and strategic initiatives,says the university worked quickly to mobilize support for the project.

With its cross-disciplinary expertise and close relationships with area hospitals, the university recognizes that its uniquely positioned to play a leadership role when it comes to these sorts of global health issues, Goel says.

We also have the benefit of having experienced the SARS outbreak in Toronto in 2003, so we know first-hand how important this sort of research can be.

The genomic testing being performed by the U of T-led group could also help researchers get a fuller picture of the mysterious illness.

Although genomic sequences of the virus were published and shared in public databases, many were deposited soon after the first cases were identified in Chinas Hubei province, according to Mubareka.

The problem is that was early on before it started going from person to person-to-person, she says, noting that viruses mutate.

There are only about 50 sequenced genomes of the virus, adds Kozak for about 48,000 confirmed cases.

Youre not getting a great snapshot, he says. Its tough to really understand a lot about the virus.

Among the nagging questions about COVID-19 that U of T and Sunnybrook researchers hope to answer are how long patients remain contagious and if the amount of the virus present in respiratory secretions is proportional to its severity.

Their work may help others understand how the virus spreads from point A to point B, and if its changing in ways that make it more dangerous.

The research team includes U of T students likeNatalie Bell, a second-year masters student in laboratory medicine and pathobiology who is also working with Mubareka on a project related to influenza from swine.

Its really interesting to see science happen in real time, especially being part of Sams lab [and] to see her involvement and the movement from lab to policy work, and how it impacts public health, Bell says.

Mubareka and Kozak plan to upload the sequencing data to public servers and share it with the world to help with epidemiological studies and vaccine design.

We will build global capacity any way that we can, Kozak says.

Mubareka and Kozak say their work was made possible thanks in part to the McLaughlin Centre, which provided emergency funding for the project. We have no shortage of ideas of things we can do to hopefully make a difference, Kozak says, but you always need someone to provide the resources to do it.

Stephen Scherer, the director of the McLaughlin Centre at U of T and a University Professor in the department of molecular genetics, says the centre wanted to make sure the researchers had the necessary funds to do their work in time.

Nobody is busier right now than this group, so we wanted to make the process as easy as possible for them, Scherer says. We also wanted these researchers to know the rest of us value their efforts to keep us safe.

Read more:
U of T and Sunnybrook virologists work on tools to combat coronavirus outbreak - News@UofT

Read More...

Global Molecular Microbiology Market Increasing Demand with Leading Player, Comprehensive Analysis, Forecast 2025 – News Times

Saturday, February 22nd, 2020

The report titled Global Molecular Microbiology Market is one of the most comprehensive and important additions to Reportspedia archive of market research diaries. It offers thorough research and analysis of major aspects including market size, market growth rate, market profitability, industry cost structure, distribution channel, market trends, and key success factors of the market.

The report includes SWOT and PESTLE analyses to provide a deeper understanding of the industry. All of the foremost companies included in the report are profiled based on gross margin, market share, forthcoming strategies, recent expansions, target customer demographics, products and applications, and other critical factors. The report also offers regional analysis of the Molecular Microbiology market with high focus on market growth, growth rate, and growth potential.

Global Molecular Microbiology Market is valued at USD XX million in 2019 and is projected to reach US$ XX million till 2025, rising at a CAGR of 7.8% during the period 2019 to 2025.

Major Players involved in the Global Molecular Microbiology Market:

Roche, Myriad Genetics, Abbott, Qiagen, Danaher (Cepheid), Illumina, Agilent, BioMerieux, Hologic, DAAN Gene, Genomic Health, BD, Foundation Medicine,

Get Free PDF Sample Report(Including Full TOC, List of Tables & Figures, Chart):https://www.reportspedia.com/report/life-sciences/global-molecular-microbiology-market-2020-by-company,-regions,-type-and-application,-forecast-to-2025/50888#request_sample

Market Competition

The vendor landscape and competitive scenarios of the global Molecular Microbiology industry are broadly analyzed to help market players gain competitive advantage over their competitors. Market players can use the analysis to prepare themselves for any future challenges well in advance. They will also be able to identify opportunities to attain a position of strength in the global Molecular Microbiology industry. Furthermore, the examination will help them to successfully channelize their strategies, strengths, and resources to gain maximum advantage.

The Essential Content Covered in the Global Molecular Microbiology Industry Report:

* Top Key Company Profiles.

* Main Business and Rival Information

* SWOT Analysis and PESTEL Analysis

* Production, Sales, Revenue, Price and Gross Margin

* Market Share and Size

The Molecular Microbiology Industry segment by regions includes:

Americas (United States, Canada, Mexico, and Brazil), APAC (China, Japan, Korea, Southeast Asia, India, and Australia), Europe (Germany, France, UK, Italy, Russia, and Spain), and Middle East & Africa (Egypt, South Africa, Israel, Turkey, and GCC Countries).

Global Molecular Microbiology Market Segmentation by Product:

By Type Molecular Microbiology market has been segmented into Quantitative PCR Detection Diagnostic Kits, Pathogenic Microorganisms Diagnostic Kits, etc.

Global Molecular Microbiology Market Segmentation by Application:

By Application Molecular Microbiology has been segmented into Human, Veterinary, etc.

Inquire Here For Queries Or Report Customization: : https://www.reportspedia.com/report/life-sciences/global-molecular-microbiology-market-2020-by-company,-regions,-type-and-application,-forecast-to-2025/50888#inquiry-before-buying

Key Questions Answered

1) What will be the size and CAGR of the global Molecular Microbiology market in 2025?

2) Which product will gain the highest request?

3) Which application could show the best development/growth?

4) What will be the competitive landscape in future?

5) Which players will lead the global Molecular Microbiology market in the coming years?

6) Which region will gain the largest share of the industry?

The report offers comprehensive analysis of the value chain, production, consumption, sales, and opportunities in the global Molecular Microbiology market. Market players can also use it to get useful endorsements and suggestions from market experts and knowledgeable industry analysts.

Table of Contents

Executive Summary

1 Industry Overview

2 Industry Chain Analysis

3 Manufacturing Technology of Molecular Microbiology market

4 Major Manufacturers Analysis

5 Global Productions, Revenue and Price Analysis of Molecular Microbiology market by Regions, Creators, Types and Applications

6 Global and Foremost Regions Capacity, Production, Revenue and Growth Rate of Molecular Microbiology industry 2015-2019

7 Consumption Volumes, Consumption Value, Import, Export and Trade Price Study of Molecular Microbiology market by Regions

8 Gross and Gross Margin Examination

9 Marketing Traders or Distributor Examination

10 Worldwide Impacts on Molecular Microbiology Industry

11 Development Trend Analysis

12 Contact information

13 New Project Investment Feasibility Analysis

14 Conclusion of the Global Molecular Microbiology Industry 2019 Market Research Report

Continued

Click here to view the full report:https://www.reportspedia.com/report/life-sciences/global-molecular-microbiology-market-2020-by-company,-regions,-type-and-application,-forecast-to-2025/50888#table_of_contents

Link:
Global Molecular Microbiology Market Increasing Demand with Leading Player, Comprehensive Analysis, Forecast 2025 - News Times

Read More...

MSU’s Beronda Montgomery recognized as one of the 100 most inspiring black scientists in America – MSUToday

Tuesday, February 18th, 2020

Beronda Montgomery, MSU Foundation Professor, was listed as one of the 100 inspiring black scientists in America byCrossTalk, the official blog ofCell Press, a leading publisher of cutting-edge biomedical and physical science research and reviews.

It is an honor to be listed among other highly accomplished, established and emerging scientists who I admire and celebrate, said Montgomery.

Montgomery has also been aCollege of Natural Sciencefaculty member since 2004 who holds joint appointments in theDepartment of Biochemistry and Molecular Biologyand theDepartment of Microbiology and Molecular Genetics.

Based on my engagement with students, both undergraduate and graduate, and early-career professionals in venues such as annual conferences, professional development workshops, campus visits and online, representation matters greatly, Montgomery said.

The inaugural list was established to help solidify the legacy of 100 accomplished scientists from African, Afro-Caribbean, Afro-Latinx and African American backgrounds in the fields of life sciences, chemistry, engineering and physics.

CrossTalk contributor Antentor O. Hinton Jr., postdoctoral fellow at the University of Iowa, and two of his colleagues recognized a pressing need to increase the visibility of black scientists and took action to highlight 75 established investigators, including Montgomery, and 25 rising stars.

The scientists were chosen based on their position, teaching and mentorship history and roles as advocates for Diversity in STEM.

Hinton hopes that illuminating these scientists through social media will underscore the necessity for diversity in the academy and encourage the next generation of young, black scientists.

We are hoping to spread the word around the science community about how to teach, train and mentor minority scientists by showing them they are not the only ones in science that look like them, Hinton said. This type of list is something that is rarely captured or recognized.

Montgomery, who is also a member of theMSU-DOE Plant Research Laboratory, was chosen for her outstanding research, commitment to creating literature about diversity and inclusion and her dedication to mentoring and developing scientists of diverse backgrounds.

Individuals with shared demographics or backgrounds have shared poignantly how meaningful it is to engage and see individuals who are further along a career trajectory on highly visible platforms, Montgomery said. In this sense, the curators of this list are providing a highly visible platform for representation and potentially recognition.

Montgomerys exemplary career has been highlighted with several honors.

She was chosen for a National Science Foundation CAREER Award and was named a fellow of the American Academy of Microbiology for seminal contributions to understanding physiological and morphogenic adaptation of photosynthetic microbes to light.

For these and other outstanding contributions to the university, Montgomery became an MSU Foundation Professor in 2016.

CrossTalk plans to publish another list in 2021. For a full listing of this years 100 inspiring black scientists, please visitcrosstalk.cell.com.

More here:
MSU's Beronda Montgomery recognized as one of the 100 most inspiring black scientists in America - MSUToday

Read More...

How one smuggled elk could have caused an ecological crisis – The Register-Guard

Tuesday, February 18th, 2020

Montana wildlife officials investigate unusual elk that they found was taken from Washington and set loose in Montana.

GREAT FALLS, Mont. It reads like a forensic crime drama and in a very real sense it is.

A Montana game warden learns of an unusual elk shot along the Rocky Mountain Front. The animal has physical peculiarities unlike anything the department has seen before. Genetic testing reveals that the young bull is of an exotic sub-species, and that it came from a herd more than 600 miles from where it was shot.

How did it get here? Who released it into the wild? What would have happened had the bull lived, intermingling for years with Montana's native elk population?

When a new disease appears in humans, pathologists make every effort to identify 'Patient Zero' the first person to become infected with the new pathogen. Finding patient zero is important because knowing that person's history can help to determine how and when the outbreak started.

This unusual 2-year-old elk harvested 16 months ago in the foothills of the Rocky Mountains is FWP's Elk Zero.

"It wasnt just an elk," remarked Dave Holland, game warden captain for Montana Fish, Wildlife and Parks, to the Great Falls Tribune. It had the ability to be an ecological disaster.

The elk with florescent antlers

On Oct. 20, 2018, a 'spike' bull elk was legally harvested north of Choteau. The hunter didn't immediately notice anything unusual about the animal, and took it to a wild game processor to have it butchered. It was there that things began to get interesting.

According to Holland, when the hunter returned to check on his order the processor asked him what the deal was with the elk's antlers. The bull's spikes had been painted orange, but the hunter hadn't noticed because he is color blind.

The elk's florescent antlers weren't its only unusual feature. When Warden Ron Duty inspected the animal's carcass he discovered it had been castrated. Duty began asking people around Choteau if they'd ever seen the elk, or knew who was responsible for it.

People had videos of this elk," Holland recalled. "It would walk right up to people. Obviously, humans had been interacting with this elk, probably since it was a calf."

Some of the locals had even given it a name "Buford" but no one claimed responsibility, nor claimed to know its origin.

The possibility that the elk had somehow escaped or been released from a regional game farm also was explored, but there was no record of a missing animal, something that would have almost surely existed had it been raised in commercial captivity.

Game farms are highly regulated," Holland noted. "They have to be fenced. All the animals have to be documented, and when they're harvested they have to be inspected.

FWP's interest in the case was motivated by more than simply idle curiosity about an unusual domesticated elk. Not knowing where Elk Zero came from, or whether it was just one member of a larger group of introduced elk, could have serious animal health implications.

The importation of any animal brings with it a full community of parasites and pathogens," explained Emily Almberg, disease ecologist for Montana Fish, Wildlife and Parks. Some things might be pretty benign, but there are things that we worry about that might be difficult to detect just by looking at an animal.

Chronic wasting disease, bovine tuberculosis and brucellosis are all diseases carried by elk, and which can be transmitted by them to other animals in some cases to livestock. Not knowing where Elk Zero had come from or what it had been exposed to was a serious consideration.

Yet, no one in the Choteau area seemed to know or would claim to know very much about it. There were, however, two individuals more directly connected to Elk Zero than the rest of the community.

FWP investigators were able to prove that two people from Choteau had been feeding the elk, which is a violation of state law.

In Montana it's a misdemeanor offense to attract wildlife of any type with food or other attractants like salt licks; the lone exception being the recreational feeding of birds. Violators face potential penalties of up to a $1,000 fine, six months in jail and a loss of their hunting, fishing, or trapping privileges.

Why feeding wildlife is a crime

Many Montanans feel a strong urge, born in compassion, to feed wild animals that appear to be struggling. Not only is feeding wildlife illegal, its also a bad idea.

People have the impression that wildlife need help; that we have to feed them to get them through the winter," said Game Warden Captain Dave Holland. "But when you put out an attractant like salt or food, you start unnaturally congregating the animals, which will help spread disease."

A recent example of this is the rapid spread of chronic wasting disease in deer congregating in and around Libby. The fatal neurological disease was unknown west of the continental divide until the spring of 2019, when a single white-tailed deer in Libby tested positive for the disease.

Since then more than 60 deer in the area have tested positive for CWD, many of them congregated in areas where people were actively feeding deer.

Feeding wildlife also habituates them to human food sources making it more likely they will be unable to survive on their own.

Youre actually doing them a disservice because if they dont learn how to forage for themselves theyre not going to survive after youve stopped feeding them," Holland notes. "It cant go on forever."

Most wildlife has evolved without humans helping them," he added. "Theyve got it figured out. They know how to survive. We don't find salt blocks in nature."

Holland said the residents were cited for feeding the elk, but repeatedly and adamantly denied having anything to do with his presence in Choteau, or to knowing who did.

"We are not saying they introduced the animal," Holland emphasized. We were able to prove they fed the animal, which is a violation of (Montana law.)

Potential impact of introduction

FWP officials were at a dead end, but there remained one possible avenue of investigation.

There was this rumor around the community that possibly this elk could have been brought to Montana from Washington," Holland said.

Holland contacted his counterpart with the Washington Department of Fish and Wildlife to see if was possible to connect Elk Zero with a herd in that state.

The possibility that Elk Zero was transported to the Choteau area from out of state added another layer of concern. Montana's elk herd belongs to a unique genetic subspecies identified as Rocky Mountain elk, which are prized by hunters for their large antlers. Those roaming the temperate forests of western Washington are Roosevelt elk, which have larger bodies, are slightly darker in color and have smaller antlers.

Despite the fact that Elk Zero had been castrated, the presence of a free-roaming bull elk, from a different subspecies and just reaching its sexual maturity, caused alarm among some wildlife managers.

If you start intertwining those populations (Roosevelt and Rocky Mountain) they lose the characteristics that made them distinct," Holland explained. "You run the risk of losing a distinct sub-species."

Almberg said its an open question whether the introduction of a single animal would make a meaningful genetic contribution, to the point where it would have any irreversible effects on the native herd. However, she does agree that cross-breeding between subspecies can result in a negative outcome for the species as a whole.

"If you mix distinct sub-species you have the potential of losing the genetics that control local adaptation," Almberg said. There is something called 'out breeding depression' where you see the decreased fitness of offspring when you cross those different subspecies, so lower reproductive output.

Finding the origin

Unlike Montana, Washington state has compiled a comprehensive genetic database of its elk herds. Wildlife geneticists there have identified 10 herds, which may intermingle at times, but maintain distinct genetic profiles.

However, submitting a single tissue sample from Elk Zero would not be enough to veritably identify it as a member of one of Washington's herds. Wildlife managers would need to obtain multiple samples collected from a variety of elk within the Choteau area to compare with the DNA profiles cataloged by Washington's Department of Fish and Wildlife.

During the remaining months of the 2018 hunting season and throughout the 2019 hunting season, FWP biologists and wardens collected 10 distinct tissue samples from elk harvested in the Choteau and Augusta areas. Along with a sample previously collected from Elk Zero, they were sent to Washington's molecular genetics laboratory in Olympia for DNA analysis.

"Using Washington state elk reference baselines, the unknown elk 1 (Elk Zero) genetically assigned to the Washington State Yakima elk herd with a positive probability of 99.98%," the lab results reported.

In other words, within a minute fraction of statistical probability, DNA testing had proven that the elk had been taken from a herd in southwest Washington; probably as a calf, and was transported to Montana where it was then released. FWP finally knew where Elk Zero had come from, but knowing that raised another concern.

Beginning in 2008, wildlife managers in Washington began receiving reports of elk with deformed, broken or missing hooves. The condition has now been identified as elk hoof disease, a bacterial infection that eventually cripples the animal, and which has now spread to parts of Oregon and Idaho.

"The disease appears to be highly infectious among elk, but there is no evidence that it affects humans," a report from the Washington Department of Fish and Wildlife states. "Currently there is no vaccine to prevent the disease, nor are there any proven options for treating it in the field."

Elk Zero tested negative for hoof disease, but keeping it out of Montana is a primary concern for herd managers.

"That lameness, the severe inflammation of hooves can cause ... a deterioration of body condition," Almberg said of the impacts of elk hoof disease. "They have a harder time moving around, they have a harder time feeding and keeping up with the herd. Those things can all contribute to lower survival."

"This hoof disease is a major issue impacting their elk herd," Holland added. We dont have it in Montana yet and we dont want it.

Who knows what the consequences would have been

At this point it appears that the illegal theft and release of Elk Zero had no impact on Montana's elk population, but that was solely due to dumb luck.

Holland acknowledges that whoever brought the animal to Montana probably didn't understand the ramifications of what they were doing, but the consequences could have been just as detrimental no matter the person's intentions.

With nearly 17 years of service as a game warden, Holland said he's never experienced anything quite like Elk Zero.

This is the first time Ive ever seen a large mammal moved from one state to another and released," he said. Ive been involved in removing fawns from houses where they were kept in the kids bedrooms, or theyre being raised as pets, but thats usually local people out walking locally and theyll bring an animal home. This is a whole different level. They literally went out and found an elk in Washington, put it in a trailer, drove it to Montana and let it go."

As an agency we move wildlife, but its highly regulated," Holland added. "Well spend years planning for and getting ready to move wildlife. If somebody just willy-nilly picks a calf elk up, throws it in a horse trailer and drives it to Montana theyre not thinking about hoof disease or CWD or the genetic aspects. Thats where this can become very dangerous to wildlife populations."

FWP District Supervisor, Gary Bertellotti, put the case of Elk Zero into the broader context of invasive species across the U.S. a problem becoming increasingly critical in Montana.

"Quagga mussels, CWD, feral pigs, lake trout we can see what the impacts are by looking at other things going on," Bertellotti said. "In all of those cases it was because somebody transported something. They all started with one person."

We dont know what that would be. Weve never had to deal with that," Bertellotti said of the implications, had Elk Zero been left fertile and undiscovered. Roosevelt elk may not be as compatible with the habitat and the weather systems we have here. If those genetics start to become more prevalent ... all of a sudden you could see that population not surviving as well as it should. It could have been anything from more susceptibility to diseases to the viability of the species. Who knows what the consequences would have been."

Closing the case

While a portion of the mystery surrounding Elk Zero has been solved, the investigation into who is responsible for taking the elk from Washington and releasing him in Montana is ongoing. Wardens in both states continue to ask questions.

What we really want to know is who brought it here," Holland said. We have a strong theory that it came from Enumclaw (a city roughly 30 miles east of Tacoma). We've developed the theory that it came from that area based upon information other than the genetics. We want contact with anybody with knowledge of how the animal arrived in Montana alive and who released it.

Just as with any crime drama, investigators hope someone will come forth with information regarding Elk Zero that will ultimately lead to an arrest.

Montana FWP maintains a confidential, toll-free hotline where people can report violations of fish, wildlife or park regulations. Since its establishment in 1985, TIP-MONT has received reports resulting in 1,521 convictions. To report a fish, wildlife or park violation call 1-800-TIP-MONT (1-800-847-6668). Callers can remain anonymous and may be eligible for a cash reward of up to $1,000. Nearly $155,000 in TIP-MONT rewards have been paid to citizens since the program was established.

I believe that there are people in Washington who have information about where this elk came from," Holland said. I believe theres people here in Montana who also know that. If they come forward with information that helps us find answers to this, then yes, absolutely theres going to be a TIP-MONT reward."

Read the original here:
How one smuggled elk could have caused an ecological crisis - The Register-Guard

Read More...

Study finds genetic link to extinct relative of humans in 4 modern West African populations – UCLA Newsroom

Tuesday, February 18th, 2020

UCLA genomic research uses statistics rather than ancient DNA to look back more than 600,000 years

Leticia Ortiz/UCLA

The UCLA researchers studied four populations that mostly live in the area marked by the white band, in West Africa.

UCLA computational biologists have discovered that four populations in West Africa can trace about 8% of their genetic ancestry to an archaic hominin, an extinct relative of humans that branched off from the hominid evolutionary tree more than 600,000 years ago about 100,000 years earlier than Neanderthals did. The study is published in Science Advances.

Over the past decade, advances in computing, statistical analysis, molecular biology and genetics have revealed a richer picture of humans and their interactions with ancient relatives, such as Neanderthals. But research on the genetic ancestry of African populations has lagged behind discoveries about people with ancestral roots in Europe.

The researchers, from the UCLA Samueli School of Engineering, analyzed modern DNA obtained from an international repository of genomic data. In the past, researchers would have needed to compare the modern DNA to so-called reference DNA from ancient fossils to draw such conclusions. But the improved statistical techniques available today enabled them to look backward in time hundreds of thousands of years without fossil DNA.

This opens a new path in understanding the complexity of human evolutionary history in Africa, where the picture hasnt been as clear, said Sriram Sankararaman, the studys principal investigator, a UCLA assistant professor with appointments in computer science, human genetics and computational medicine.

The archaic hominin identified in the UCLA research is a close evolutionary relative of humans.

There is not a lot known about these archaic hominins, which makes finding out how this ghost population fits into human evolutionary history challenging. But our findings are very exciting, said Sankararaman, who also is a member of UCLAs Bioinformatics Interdepartmental Program.

Previous genomic studies have presented evidence that modern populations in Africa have complex genetic lineages, in which humans and close evolutionary relatives intermixed as recently as just a few thousand years ago. But this study may provide the strongest evidence yet that this intermixture took place.

The UCLA research reveals much more of that story for the four modern groups of people, the Yoruba of Nigeria, the Mende of Sierra Leone, the Esan of Nigeria and the Gambian in Western Divisions of Gambia.

We dont need reference DNA from fossils of the archaic hominin to confirm that, somewhere deep in our ancestry, humans intermixed with them, Sankararaman said. We can now see that such events took place by looking at our DNA itself.

Segments of Neanderthal DNA extracted from fossils have been found in most modern populations outside of Africa. DNA has also been extracted and analyzed from the more recently discovered Denisovans, another extinct group of archaic humans, whose DNA is found in people living today in South Asia and Oceania.

Archaeological evidence shows that modern and archaic humans coexisted in Africa, and some fossils have features that suggest mixing between the two populations. However, usable DNA has not yet been extracted from archaic human fossils that have been found in that region which is why the researchers ability to draw conclusions about evolution without reference DNA information could go such a long way toward solving previously unanswered questions.

Although the researchers found evidence of the archaic populations DNA in modern humans, the findings are not clear enough to determine whether these two distinct populations intermixed just once or several times over hundreds of thousands of years.

Sankararaman and Arun Durvasula, a UCLA graduate student studying human genetics, used two new statistical methods that look for patterns in the genome that could reveal the presence of DNA from a distantly related unknown archaic population. They looked at genomic data of 405 people from the1000 Genomes Project, an international public repository of genomic data from around the world. The results of both analyses were consistent.

The research was supported by the National Science Foundation, the National Institutes of Health, the Alfred P. Sloan Foundation and the Okawa Foundation.

Read more here:
Study finds genetic link to extinct relative of humans in 4 modern West African populations - UCLA Newsroom

Read More...

Estimating the Probability of Regulatory Registration Success – Regulatory Focus

Tuesday, February 18th, 2020

This article discusses how to estimate the probability of regulatory/registration success for pharmaceutical products in development. The authors define the factors and methods used to assess regulatory/registration success and offer objective and data-driven methods to define probabilities for the purposes of documenting specific factors and/or risks relative to a likelihood of success. They provide a case study demonstrating how to use data and make estimate adjustments based on a variety of factors specific to individual programs. While this example applies to a drug and the US Food and Drug Administration (FDA), the same strategic approach can be applied to biologics, medical devices and combination products under review with any global regulatory Health Authority (HA).The article is based on a presentation by the authors at RAPS Regulatory Convergence in September 2019.IntroductionDetermining the Probability of Regulatory Success (PRS) for a product approval is a key driver for ensuring business/market readiness, including prioritization for the purposes of budgeting and resource planning. When considering PRS, a decision sciences approach focusing on facts is critical for avoiding biases. To do this consistently requires an ability to evaluate a program and create an objective PRS in a concise, well-documented, transparent manner along with objective, analytically driven decision-making. While a gut feeling about regulatory success may be based on experience and regulatory acumen, it cannot be objectively revised for changes in the regulatory environment and does not allow for a documented, well-vetted strategic and holistic analysis of the risks (downward adjustment) or strengths (upward adjustment) of regulatory considerations. Furthermore, gut-feeling does not support development of actionable mitigation strategies based on facts. Thus, this approach provides an objective framework for forming comparable assessments across a variety of projects.Technical vs. Regulatory SuccessIt is important to note that technical and regulatory success are different objectives and need to be assessed separately. Probability of Technical Success (PTS) applies to the probability a given clinical trial/study will be successful based on pre-defined endpoints, feasibility and other factors. Probability of Regulatory Success (PRS) is about whether FDA or another regulatory authority will grant approval for a product and based on factors within the scope of regulatory affairs, which often includes evaluation of the HAs perspective regarding the clinical relevance for a particular endpoint as it applies to suitability for defining efficacy in the context of an approval application for registration. The overall probability of success will need to consider both the PRS and the PTS and is calculated as PTRS = PRSxPTS.Six Elements of Good Decision MakingThere are six elements for good decision-making.Figure 1. Six Elements1

Read more:
Estimating the Probability of Regulatory Registration Success - Regulatory Focus

Read More...

Molecular Microbiology Market Global Production, Growth, Share, Demand and Applications Forecast to 2025 – Keep Reading

Tuesday, February 18th, 2020

Global Molecular Microbiology Market 2019 by key players, regions, type, and application, forecast to 2025. Molecular Microbiology Market Report contains a forecast of 2019 and ending 2025 with a host of metrics like supply-demand ratio, Molecular Microbiology Market frequency, dominant players of Molecular Microbiology Market, driving factors, restraints, and challenges. The report also contains market revenue, sales, Molecular Microbiology production and manufacturing cost that could help you get a better view of the market. The report focuses on the key global Molecular Microbiology manufacturers, to define, describe and analyze the sales volume, value, market competition landscape, market share, SWOT analysis and development plans in future years.

Download Free Sample Copy of Molecular Microbiology Market Report: https://dataintelo.com/request-sample/?reportId=110545

The report provides information on trends and developments and focuses on market capacities, technologies, and the changing structure of the Molecular Microbiology Market . The new entrants in the Molecular Microbiology Market are finding it hard to compete with the international dealer based on quality and reliability.

Major Players included in this report are as follows RocheQiagenIlluminaAbbottHologicBioMerieuxDanaher (Cepheid)Myriad GeneticsDAAN GeneAgilentGenomic HealthBDFoundation Medicine

Molecular Microbiology Market can be segmented into Product Types as Quantitative PCR Detection Diagnostic KitsPathogenic Microorganisms Diagnostic Kits

Molecular Microbiology Market can be segmented into Applications as HumanVeterinary

Molecular Microbiology Market: Regional analysis includes: Asia-Pacific (Vietnam, China, Malaysia, Japan, Philippines, Korea, Thailand, India, Indonesia, and Australia) Europe (Turkey, Germany, Russia UK, Italy, France, etc.) North America (United States, Mexico, and Canada.) South America (Brazil etc.) The Middle East and Africa (GCC Countries and Egypt.)

Buy the full version of this report at: https://dataintelo.com/checkout/?reportId=110545

Influence of the Molecular Microbiology Market report: Comprehensive assessment of all opportunities and risk in the Molecular Microbiology Market. The Molecular Microbiology Market recent innovations and major events. A detailed study of business strategies for growth of the Molecular Microbiology Market-leading players. Conclusive study about the growth plot of Molecular Microbiology Market for forthcoming years. In-depth understanding of Molecular Microbiology Market-particular drivers, constraints and major micro markets. Favourable impression inside vital technological and market latest trends striking the Molecular Microbiology Market.

Objective of Studies: 1. To provide detailed analysis of the market structure along with forecast of the various segments and sub-segments of the global Molecular Microbiology Market. 2. To provide insights about factors affecting the market growth. To analyse the Molecular Microbiology Market based on various factors- price analysis, supply chain analysis, Porte five force analysis etc. 3. To provide historical and forecast revenue of the market segments and sub-segments with respect to four main geographies and their countries- North America, Europe, Asia, Latin America and Rest of the World. 4. To provide country level analysis of the market with respect to the current market size and future prospective. 5. To provide country level analysis of the market for segment by application, product type and sub-segments. 6. To provide strategic profiling of key players in the market, comprehensively analysing their core competencies, and drawing a competitive landscape for the market. 7. To track and analyse competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments in the global Molecular Microbiology Market.

Customize Report and Inquiry for The Molecular Microbiology Market Report: https://dataintelo.com/enquiry-before-buying/?reportId=110545

The huge assortment of tables, graphs, diagrams, and charts obtained in this market research report generates a strong niche for an in-depth analysis of the ongoing trends in the Molecular Microbiology Market. Further, the report revises the market share held by the key players and forecast their development in the upcoming years. The report also looks at the latest developments and advancement among the key players in the market such as mergers, partnerships, and achievements.

In short, the Global Molecular Microbiology Market report offers a one-stop solution to all the key players covering various aspects of the industry like growth statistics, development history, industry share, Molecular Microbiology Market presence, potential buyers, consumption forecast, data sources, and beneficial conclusion.

About DataIntelo: DATAINTELO has set its benchmark in the market research industry by providing syndicated and customized research report to the clients. The database of the company is updated on a daily basis to prompt the clients with the latest trends and in-depth analysis of the industry. Our pool of database contains various industry verticals that include: IT & Telecom, Food Beverage, Automotive, Healthcare, Chemicals and Energy, Consumer foods, Food and beverages, and many more. Each and every report goes through the proper research methodology, validated from the professionals and analysts to ensure the eminent quality reports.

Contact Info DataIntelo Name Alex Mathews Email [emailprotected] Website https://dataintelo.com Address 500 East E Street, Ontario, CA 91764, United States.

Read more:
Molecular Microbiology Market Global Production, Growth, Share, Demand and Applications Forecast to 2025 - Keep Reading

Read More...

Turkish doctor creates first see-through 3D maps of human kidney and eye – Daily Sabah

Tuesday, February 18th, 2020

A Turkish doctor and his 15-member team have managed to render transparent 3D models of the human eye and kidney in what the scientific community heralds as an important development in organ production, the fight against cancer and even the mapping of the brain.

Genetics and neuroscience specialist Dr. Ali Ertrk, the director of the Institute for Tissue Engineering and Regenerative Medicine at Helmholtz Zentrum Mnchen and also principal investigator at the Institute for Stroke and Dementia Research at Ludwig Maximilian University's hospital, talked about their pioneering project in which they used microscopic imaging technology to reveal underlying complex structures of human organs by making them see-through. Their findings were published in the scientific journal Cell on Feb. 13.As part of the final stage of their project, Ertrk said they developed a new technology called SHANEL (Small-micelle-mediated HumAN organ Efficient clearing and Labeling) which is essentially a 3D laser microscope that can scan large tissues. Up until now, scientists had only managed to obtain cellular views of intact mouse organs in 3D. The chemicals used to turn mouse organs see-through did not work on human parts because of the accumulation of insoluble molecules including collagen over many years. After many trials, the team discovered CHAPS, a detergent that could seep into thick human organs and turn them transparent.

"We started these studies three years ago. In order to make 3D maps of these organs at a cellular level, we first had to make them visible under a laser microscope. Last year, we succeeded in making organs donated from cadavers transparent with various chemical solutions, as if turning milk into water," Demirren News Agency (DHA) quoted Ertrk as saying."We also developed an artificial intelligence algorithm that reduces the analysis of millions of images that we have obtained from the microscope, which would normally take humans centuries to analyze, down to just a few hours. Thus, for the first time in the world, we were able to make a 3D map of the human kidney and eye at the cellular level," he added.

The method could become a key technology for mapping intact human organs in the near future and hence "dramatically accelerate our understanding of organs such as the brain, their development and function in health and disease," explained Ertrk.

He said they believe that Shanel can help map the human brain at a molecular level and produce artificial human organs at a cellular level thanks to the 3D-bioprinting technology. Ertrk said they are currently working on mapping major organs such as the heart, kidney and pancreas.

"There is a huge shortage of organ donors for hundreds of thousands of people. The waiting time for patients and the transplantation costs are a real burden. Detailed knowledge about the cellular structure of human organs brings us an important step closer to creating functional organs artificially on demand," the biotech specialist said in a press release.

Read more from the original source:
Turkish doctor creates first see-through 3D maps of human kidney and eye - Daily Sabah

Read More...

Edited Transcript of VRT.AX earnings conference call or presentation 17-Feb-20 10:00pm GMT – Yahoo Finance

Tuesday, February 18th, 2020

Half Year 2020 Virtus Health Ltd Earnings Call

Greenwich Feb 18, 2020 (Thomson StreetEvents) -- Edited Transcript of Virtus Health Ltd earnings conference call or presentation Monday, February 17, 2020 at 10:00:00pm GMT

TEXT version of Transcript

================================================================================

Corporate Participants

================================================================================

* Glenn Powers

Virtus Health Limited - CFO & Company Secretary

* Susan Channon

Virtus Health Limited - CEO, MD & Director

================================================================================

Conference Call Participants

================================================================================

* David Andrew Stanton

Jefferies LLC, Research Division - Equity Analyst

* Thomas Godfrey

UBS Investment Bank, Research Division - Analyst

================================================================================

Presentation

--------------------------------------------------------------------------------

Operator [1]

--------------------------------------------------------------------------------

Thank you for standing by, and welcome to the Virtus Health Limited Half Year FY '20 Results Conference Call. (Operator Instructions)

I would now like to turn the call over to Ms. Sue Channon, CEO. Please go ahead.

--------------------------------------------------------------------------------

Susan Channon, Virtus Health Limited - CEO, MD & Director [2]

--------------------------------------------------------------------------------

Thank you, and welcome to the Virtus Health FY '20 Half Year Results, and thank you for joining us. Virtus has demonstrated resilience and outperformed overall market volume growth in Australia. We have focused on improving profitability through cost reduction initiatives, which will be realized in future periods, and our investments in infrastructure in FY '19 have facilitated business development opportunities and growth. It's Virtus' diversified model, scale and geographical reach that provides an unrivaled platform for participation in all key fertility segments, both domestically and internationally, and it has delivered.

Story continues

Moving to Slide 4 and the financial results highlights. Virtus overall fresh cycle growth for the half year was up 1.3% with a total of 10,649 fresh cycles compared to 10,513 cycles in the prior corresponding period. Revenue was up 1% to $142 million on the prior corresponding period, and EBITDA was up 21.9% to $39.5 million, noting that $7.4 million of the increase was the result of adopting the new lease accounting standard.

Australian segment EBITDA increased 18.8% to $39.7 million. Again, $5.9 million of this increase was a result of the new standard. And International segment EBITDA increased 22.7%. Again, $1.5 million of this increase was from the adoption of the new lease standard.

NPAT attributable to ordinary equity holders was up 2.3% to $15 million with earnings per share up 2.4% to $0.1865. Headline earnings have been impacted by fair value gains on put options, lower interest costs and CEO transition and recruitment costs. The company has declared an interim dividend of $0.12 per share fully franked, unchanged from the prior year and payable on the 16th of April.

Turning now to Slide 5. Against the backdrop of a competitive business reproductive services market, we have responded accordingly and maintained our Australian market leadership position. We have adjusted our service model to the patient mix and changes in the market and continued the activities we started in FY '19 to remove cost in the business, which will deliver further benefits in future periods. As a result of our focus on patient care models, Virtus outperformed overall market growth in Australia, and cycle activity in the half increased 2.7% compared to an increase in Virtus available market of 1.2%. Notably, Australian IVF clinic EBITDA increased 4.5%, excluding the impact of the AASB 16 lease standard.

We have delivered strong growth in our Australian TFC low price clinics. And while our Victorian premium cycles were stable and Queensland grew, lower premium cycle volumes in New South Wales have impacted EBITDA, pathology revenue and IVF-related Day Hospital revenue in New South Wales. The investments made through FY '19 new Day Hospital facilities and our focus on business development are starting to deliver, with non-IVF Day Hospital procedure volume increasing 5.7%. International operations maintained EBITDA despite softer volumes, and we have seen EBITDA improvements in Ireland, Singapore and the U.K.

Management's focus on cost-out initiatives for margin improvement continued. However, overall corporate costs were impacted by CEO transition, recruitment and restructuring initiatives, which will deliver improved EBITDA margins in future periods.

Moving to Slide 6. And the Australian segment performance saw revenue up 0.3% to $112.8 million. And Australian segment EBITDA, including the impact of the new lease standard implementation of $6 million, increased to $39.7 million. The initiatives that we'll continue to deliver on this improved position are summarized on Slide 7.

So moving to Slide 7. In our summary at the end of FY '19, we noted that our focus in Australia will be on defending and building premium services, growing low price volumes, growing diagnostic revenue and growing non-IVF Day Hospital revenue.

Available market share increased to 40% in the first half compared to June 2019 closing position of 39.6%. Virtus cycle growth is 2.7% year-to-date compared to an available market growth of 1.2%. Virtus premium service remains our focus. And year-to-date, our premium cycle volume is up in 3 states of Queensland, Victoria and the ACT. Softer market conditions led to a reduction in our New South Wales and Tasmanian volumes. However, additional doctor recruitment is in progress in both states, in parallel with leadership changes guiding operational and cost-out initiatives.

Our TFC low price clinic saw volume growth of 30.2%, with low price cycles now representing 22% of overall volumes compared to 17.3% in the prior corresponding period. Overall, Australian Reproductive Services EBITDA margins have been impacted slightly and are down 0.5%, excluding the AASB 16 lease impact.

Diagnostic initiatives have not yet delivered with revenue flat as a result of lower pathology and PGT volumes, resulting in a less favorable revenue mix. Cost management initiatives have been implemented to align with volume softness, and there's a focus on increasing testing utilization within the new Revesby laboratory to drive internal and external referrals and utilization.

In our Day Hospital, non-IVF revenue growth of 6.8% has been achieved following business development initiatives in the 2 new Day Hospitals commissioned last year. Endoscopy procedures have been established in both facilities and are expected to deliver improved performance in the second half.

Moving to Slide #8 and the Australian ARS operations. Virtus Australia's overall cycle activity increased 2.7% in the first half to 8,302 cycles compared to an available Eastern Seaboard market volume increase of 1.2%, with a resulting EBITDA increase of $1.3 million. Virtus Victoria grew 10.2% on the prior corresponding period against a market growth of 1.7%. Premium cycle volume was stable with growth predominantly in low-cost services. Virtus Queensland grew 6.2% on the prior corresponding period against the market growth of 4.4%. Virtus New South Wales, including the ACT, declined by 3.4% on the prior period against the market decline of 0.5%. We had some movement of a few doctors due to retirement and international relocations that impacted this. And Virtus Tasmania declined by 20.3% on the prior period against a market decline of 5%, doctor resources again being the issue in Tasmania.

Virtus has continued to proactively target the low-cost segment with ongoing service model and pricing reviews and delivered a volume increase of 30.2% across the fertility center network with improved performance across all states. The TFC now represent 22% of Virtus Australia cycle volume against 17.3% in the prior period. And whilst we've experienced a small decrease in our EBITDA margins overall as a result of our targeted low price initiatives, EBITDA margins within our TFC to remain in excess of 35%.

Moving to Slide 9. Virtus Diagnostics revenue increased 0.2%, and EBITDA decreased 30.2% over the prior period as a result of less favorable revenue mix and cost. This was caused by continued softness in PGT utilization declining to 12.9% of fresh cycles from 14.6% in the prior corresponding period, impacting margin, and increased compliance costs as a result of the change in NPAAC supervision requirements. The first half FY '20 costs are recorded with a full half year impact compared to only 3 months in the prior period.

We will focus on further growth in Diagnostics by driving internal and external referrals to utilize increased capacity and expanded testing capability in the relocated laboratory supported by the additional scientific and pathologist resources; the introduction of new technologies for noninvasive PGT, which continues through the validation process and molecular genetics; and cost-out initiatives to align with volume.

Diagnostics continues to be an important part of our Virtus integration platform, and we are focused on growing the utilization of these investments made through FY '19 for an improved performance.

Moving to Slide 10 and the day -- Australian Day Hospital operations. The Day Hospitals experienced a difficult year in FY '19 as a result of the delays in commissioning the planned facility development. However, the first half FY '20 has seen an improvement in utilization and business development continues, delivering an increase of 6.8% on the prior corresponding period in non-IVF Day Hospital revenue across all Specialist Day Hospitals.

Overall Day Hospital EBITDA was flat as non-IVF growth was offset by lower IVF procedures impacted mainly by softer premium cycle volume in New South Wales. Business development has delivered a $300,000 EBITDA improvement over the prior period in Alexandria as more non-IVF surgery is secured. And whilst Hobart Specialist Day Hospital is still in early stage of business development, an operational restructure was completed in December 2019. And with the first endoscopy list commencing on the 13th of February, the outlook is more positive.

Moving to Slide 11. We have continued to diversify our revenue since listing through our international operations, which are now 21% of group revenues. We have made good progress through the half and have delivered earnings improvement in 3 territories: Ireland, Singapore and the U.K. International segment revenue is up 3.5% to $29.2 million, and segment EBITDA is $6.8 million.

And looking at the Irish operations on Slide 12. In Ireland, despite fresh cycle volume softness, we have seen EBITDA improvement of 17.1% on the prior period as a result of cost management initiatives. 1,075 cycles performed in the half compared to 1,094 in the prior period. Revenue was flat at EUR 10.5 million despite the lower fresh cycle volumes, which were offset by an increase in frozen cycles.

Moving to Slide 13. In our Danish operations, EBITDA overall was down on the prior period. 849 cycles performed in the half against 930 in the prior period. Revenue across the Danish clinics was down 7.5% at DKK 25.6 million. EBITDA, local currency, was down 45.9% on the prior period. Cycle volume was impacted by changes to Swedish donor regulations, reducing IVF tourism into Denmark. Short-term doctor resourcing issues impacting performance in Aagaard have now been addressed, and the clinic is fully resourced at December 2019. Management resources have been strengthened in Denmark to focus on business development and growth.

Moving to Slide 14. Complete Fertility has improved revenue and EBITDA performance this half from stronger donor activity and improved activity from the National Health Service. Complete Fertility performed 215 fresh cycles against 228 in the prior period, and revenue was up 13.4%. EBITDA was up 125% over the prior period driven by revenue initiatives and effective cost management.

And Singapore continued its positive performance with 208 cycles against 176 in the prior period. Revenue is up 13.5%, and EBITDA is up 77.4% on the prior period. The Singapore team has just celebrated their fifth year anniversary and continues to delight with consistently high patient survey results and the NPS score leading our group and benchmark for pregnancy and live birth success rates the highest across our network.

I'll now pass you over to Glenn Powers, CFO, to provide the detailed financial summary.

--------------------------------------------------------------------------------

Glenn Powers, Virtus Health Limited - CFO & Company Secretary [3]

--------------------------------------------------------------------------------

Thank you, Sue. Good morning, everybody, and turning to Page 17. So the statutory results, obviously, for Virtus, as with most companies, there is quite an influence of AASB 16, the new leasing standard. I think we just put it straight down to the bottom, the profit after income tax attributable to ordinary equity holders, that is up by 2.3% overall. The net AASB 16 impact on that was to reduce that NPAT number by approximately $200,000. Obviously, within the body of the P&L, you've got movements in terms of the segment EBITDA, the depreciation number and also the interest number. And those are noted at the bottom of the page, the actual numbers.

Looking at Slide 18, we just call out the net movement from noncash transactions, transaction expenses and also, this time, the CEO transition costs. And you can see there, there was a fair value adjustment related to the settlement of the final options in respect of Ireland and Tasmania. And I think the other cost movements are pretty much self-explanatory.

Slide 19, we do provide a detail of our AASB 16 adjustments. I don't propose to go through that in detail, but you can see there is that net decrease or that net impact to the actual profit after income tax of $0.02 million.

Turning to Slide 20. I think Sue has covered, obviously, a lot of the key drivers for the revenue and group EBITDA. I think a couple of key points to note. Firstly, Australian IVF clinic EBITDA increased by 4.5%. So we think that's a pretty positive result given the change in mix. So we have seen continued shift and increase towards more low price IVF. But the businesses have responded very well in terms of their operational management, and we have seen that 4.5% increase in our core clinic EBITDA.

We also saw EBITDA growth in Ireland. That was at 17%, so that was a very, very positive result there. And Singapore has continued to improve its EBITDA. U.K., which gave us a little bit of an issue last year, U.K., we've actually seen a recovery in performance and, again, a combination of good development of the business around our core IVF activity but also good cost management as well.

Two main headwinds, really, that we saw in the second -- in the first half with Diagnostics EBITDA and the impact of a shift in revenue mix away from the PGT activity. And also, as Sue said, we absorbed the full year -- a full half year of the compliance cost increase in this half. The other area was very much Denmark. Denmark, the doctor resource change in the Swedish donor market were both significant factors in the first half. But the businesses are very much set up now for the second half. We have doctors in place. We've added doctors in both clinic locations. So we do anticipate an improvement in performance in our Danish businesses in the second half.

I think we've covered the leasing position extensively. So again, although the movements don't look significant, in some ways, I think there are some positives around individual clinic performance and particularly our core Australian business.

Cash performance on Slide 21. We actually saw a very focal performance compared to the prior year comparison. And again, unfortunately, leasing does impact 2 or 3 numbers there: so the group EBITDA number, the lease interest number and also the lease principal payments number. They all flowed from the AASB 16 adjustments. But some of the core factors that actually show -- led to that improved cash performance, lower CapEx. Last year, fiscal year '19 was a big year in terms of capital expenditure. This year is more modest. And most of the CapEx this year continues to be around technology and laboratory enhancements, primarily EmbryoScope in 2 or 3 locations we've added the facility. We also saw improved working capital in this half, and that contributed to a turnaround of $9 million in free cash flow after dividends compared to the prior year.

Slide 22, the statement of financial position. Again, AASB 16, obviously, it impacts the net asset -- net financial position. So the net asset reduction includes a net impact of $8.7 million resulting from that new accounting standards, and that's covered in the first part of the slide. Dividend proposed, no change in this half year, so the dividend of $0.12 per share, fully franked, will be payable on the 16th of April. Sue?

--------------------------------------------------------------------------------

Susan Channon, Virtus Health Limited - CEO, MD & Director [4]

--------------------------------------------------------------------------------

Thanks, Glenn. So moving to Slide 23 and our summary. Fertility, as we have talked about previously, affects 1 in 6 couples' reproductive age worldwide, and the social and demographic factors that contribute to this global dynamic continues to drive demand for ARS. Our strategy has been to ensure that Virtus has the platform to self-sustain ongoing growth. And investments in people, technology and additional day hospital and diagnostic capacity support this strategy, the outcome of which is evident in our first half FY '20 results. As we continue to develop our approach and model to ensure we remain relevant to the patients we treat and the markets in which we operate, our network is well established in the all-patient demographics. Revenue growth will be achieved through a combination of service expansion and market penetration.

Our strategy is to focus on defending and building the premium ARS business, and we remain committed to growing our service and presence within the low price segment. Our day hospital strategy has seen a focus on attracting non-IVF surgical activity to our improved facility, and this is delivering. Our diagnostic throughput will be enhanced through our research into NIPT and business development activities to maximize internal and external diagnostic and genetic referrals. We have made good progress through the half across the international business and have addressed performance, resourcing and cost-out initiatives. And our international operations continue to contribute positively to the diversification of our revenue.

Our focus on margin improvement is ongoing with efficiencies and cost savings expected through recent management restructures and a greater emphasis on process improvements to ensure optimal patient care and experience. We have a very clear program of work to drive earnings growth through our cost-out initiatives, many of which have been completed in the first half. We are well positioned to deliver further earnings improvement across Virtus in the second half.

As you know, Kate Munnings will join Virtus on the 4th of May. Kate, most recently Chief Operating Officer with Ramsay Health Care Limited's Australian business, has a successful track record leading commercial improvement, organizational and business transformation across multiple sectors and industries. Kate's relevant experience, especially alongside specialist doctors, means she's well equipped to lead Virtus Health and the continued delivery of exceptional services to patients. I had the pleasure of having dinner with Kate last week, and I believe the organization is in good hands. I am confident she will continue to lead Virtus successfully into the next phase.

Glenn and I will be happy to take questions regarding Virtus Health results now.

================================================================================

Questions and Answers

--------------------------------------------------------------------------------

Operator [1]

--------------------------------------------------------------------------------

(Operator Instructions) Our first question is from David Stanton, Jefferies.

--------------------------------------------------------------------------------

David Andrew Stanton, Jefferies LLC, Research Division - Equity Analyst [2]

--------------------------------------------------------------------------------

First, I'd like to say a big thank you to Sue for all her help over the years. You'll be greatly missed. But my first question is, as an overall statement in Australia, can you give us an idea of why you think the premium market as you see it is declining?

--------------------------------------------------------------------------------

Glenn Powers, Virtus Health Limited - CFO & Company Secretary [3]

--------------------------------------------------------------------------------

Yes. I think the -- if we look at it -- well, the interesting thing is that it's not across -- it's not consistent across states. For example, we actually saw good growth in our Queensland premium service in the first 6 months. Victoria, we were stable in terms of the market. I think if you look at New South Wales, which is obviously the biggest market, the market was down generally in New South Wales. So of all the 3 big states, New South Wales was, by far, the weakest state in terms of market performance. So okay now, I don't think we feel necessarily that the premium is in decline. There's been a bit of talk overnight around fertility rates. And I think it is important just to note that the utilization rate of IVF continues to increase. And we've seen that again in the latest reports and comparing [ANZA] birth information compared to national birth numbers. So I think what we are just continuing to see is premium is possibly stable, but the growth in the sector does continue to be TFC/low price IVF. So -- and I think our record in the first 6 months shows that. Whether in New South Wales -- I think there may have been some local market conditions that have impacted the general state of the market in New South Wales, I think we'll see that over time in the next 6 to 9 months.

--------------------------------------------------------------------------------

Susan Channon, Virtus Health Limited - CEO, MD & Director [4]

--------------------------------------------------------------------------------

And David, sorry, as we've talked about previously, there will always be patients where the low-cost service is just not suitable. So the PGs, the genetics, et cetera, where patients will always need access to those higher-end services.

--------------------------------------------------------------------------------

David Andrew Stanton, Jefferies LLC, Research Division - Equity Analyst [5]

--------------------------------------------------------------------------------

Very good. Understood. And stop me if I'm wrong, regarding international, there were like 1 or 2 that weren't like this, but international cycles have decreased pretty much across the board. Is it -- would it be fair enough to say that that's due to the rest of the world playing catch-up on increasing the amount of frozen cycles or the fresh cycles, please, that we saw maybe 2 years ago in Australia?

--------------------------------------------------------------------------------

Glenn Powers, Virtus Health Limited - CFO & Company Secretary [6]

--------------------------------------------------------------------------------

Yes, we have seen a little bit of that. Certainly, in Ireland, we've seen that shift on more frozen cycles. So the business mix has changed a little bit. Again, if you look at the impact on our results then, our Irish business has improved EBITDA by 17% in the half. So it's sort of a bit of a natural evolution, it comes to a finite point. And we've seen that in the Australian sector. A couple of years ago, people were saying that it will be a one-for-one relationship between fresh and frozen, and that hasn't transpired. So yes, we've seen a little bit of transition as well in the Danish market. I think if you look at the Danish market, our volume decline, which is a good part of the decline in the international cycle, it has been more around doctor resource. So I think we feel we've got the doctor resource in place in both of our clinics now, and we'd like to think that we can see some business development activities, particularly in Denmark, in the next few months. And we'd like to think that we'll see our Danish business grow cycles in over the next 12 months.

Link:
Edited Transcript of VRT.AX earnings conference call or presentation 17-Feb-20 10:00pm GMT - Yahoo Finance

Read More...

Belarus, Egypt to sign intergovernmental program in education – Belarus News (BelTA)

Tuesday, February 18th, 2020

MINSK, 17 February (BelTA) Belarus and Egypt are planning to sign an intergovernmental executive program in higher and postgraduate education, Ambassador Extraordinary and Plenipotentiary of Belarus to Egypt Sergei Terentiev said in an interview with BelTA.

The ambassador spoke about the Belarus-Egypt relations in education. Thus, the National Academy of Sciences of Belarus and the Academy of Scientific Research and Technology of Egypt signed a cooperation agreement to implement five joint research projects in crop farming, nanomaterials, molecular genetics and metallurgical science.

Belarus also invited Egypt to implement projects in e-government, digital transformation, computer games and training of IT personnel. Last year Belarus issued, for the first time, educational grants to citizens of Egypt for the bachelor and master's degree programs in Belarus.

The diplomat noted that some Belarusian universities signed agreements on cooperation with Egyptian colleagues. Belarusian National Technical University (BNTU) and Tabbin Institute for Metallurgical Studies are working to set up a joint engineering department.

Currently the parties are working to arrange a visit of the minister of higher education and scientific research of Egypt to Belarus in 2020.

Read more:
Belarus, Egypt to sign intergovernmental program in education - Belarus News (BelTA)

Read More...

The Chemical Imbalance Theory of Depression: Where Is It Going? – James Moore

Tuesday, February 18th, 2020

The spurious chemical imbalance theory of depression is arguably the most destructive thing that psychiatry has ever done. Worldwide, millions of individuals are taking antidepressants, often with a cocktail of other drugs, because they have been told the blatant falsehood that they need the pills to combat a brain illnessa real illness just like diabetes.

Many of these individuals were told the additional lie that they needed to take the pills for life and are now addicted to the products.

At the present time, some psychiatrists and psychiatric facilities are backing away from the hoax. Most of these recantations take the form: We didnt mean it literally. The chemical imbalance thing was just a metaphor.

But what needs to be stressed is that the impetus for these diluted recantations came, not from psychiatry, but rather from the anti-psychiatry movement. It was the thousands of protesting voices that finally persuaded psychiatry that some backing off was needed, particularly as no proof of the theory had ever been uncovered.

The response from psychiatry, however, has not been commensurate with the damage done. What we need to see are full page ads in all major newspapers and cyber news outlets acknowledging that the chemical imbalance theory was a hoax; that it induced millions of people worldwide to take these drugs; and that it was developed and propagated to increase psychiatrys prestige and earnings. But thats not what we are seeing.

Instead, the general response from psychiatry continues to be one of denial, minimization, and excuse-making. The very eminent and learned Ronald Pies, MD, is the master of denial in this area, but minimizers and self-excusers abound. We are told that patients needed a simple formula for understanding their problems. They didnt. They needed the truth. We are told that patients needed a biological explanation to reduce stigma and alleviate their feelings of guilt. They didnt. They needed valid explanations. Besides, biological explanations actually increase stigma (here, here, here, and here).

The essential point is that as the drugs began to come on stream in the 50s, 60s and 70s, psychiatry needed illnessesreal illnesses with clear-cut biological etiologiesto cash in on the pharma-generated bonanza. Real illnesses were not to hand, so they invented their various chemical imbalance theories and promoted them as fact with all the vigor and energy that they could muster. Since then, psychiatrists have produced a truly overwhelming volume of research all aimed at proving the theory correct, but with no success. The simplistic shortage-of-serotonin-in-the-brain nonsense remains stubbornly unproven. As mentioned above, psychiatrists have backed off the more blatant expressions of this theory, but, remarkably, the treatments remain the same: Take these pills every day and come back in three months for more.

All of which is very interesting. But of even more interest is the recent development of a new approach to validatingor rather attempting to validatepsychiatric illness.

In JAMA Psychiatry, October 2019, Kenneth Kendler, MD, published an essay titled From Many to One to Many-the Search for Causes of Psychiatric Illness. Dr. Kendlers essential thesis is as follows. Prior to about 1850, causes of illness were anecdotally recorded from individual cases, resulting in long and diverse lists for all disorders. In the second half of the nineteenth century, single causes were found for many infectious diseases. Causal thinking shifted from multicausal approaches to monocausal theories of etiology. Dr. Kendler writes, Indeed proving monocausal etiology became a way to establish the legitimacy of a disorder. In the mid 20th century, general medicine shifted to a chronic disease model in which paradigmatic disorders, such as cancer and cardiovascular disease, were shown to be highly multicausal. Psychiatry, however, continued to pursue monocausal theories in their attempt to legitimize their activity. Despite ample evidence to the contrary, monocausal thinking continues to influence our field, for example, in the popular but improbable view that we can, with a few key advances, move easily from descriptive to etiologically based diagnoses.

Dr. Kendler works for Virginia Commonwealth University. He is a Distinguished Professor of Psychiatry, Professor of Human Genetics, and Director of the Virginia Institute of Psychiatric and Behavioral Genetics. He served on the DSM-III-R Work Group, on the DSM-IV Task Force, and on the DSM-5 Work Group for mood disorders.

Dr. Kendlers essay highlights two main themes: firstly, that psychiatry is not blameworthy in the promotion of spurious and monocausal etiologies; and secondly, that even though the quest has failed dismally, this is not a problem because a multicausal approach is better anyway.

Here are some pertinent quotes from Dr. Kendlers paper, interspersed with my thoughts and observations.

The second epidemiologic phase, termed infectious disease, had as its paradigm the germ theory, lasted roughly from 1850 to 1950, and was dominated by monocausal etiologic theories in which the relationship between putative etiologic agents and specific diseases was one to one (although most investigators recognized such modifying factors as host resistance). The third epidemiological phase, termed chronic disease, had a dominant black box paradigm. It incorporated a multifactorial disease model for what was termed chronic noncommunicable diseases (eg, diabetes, heart disease, certain forms of cancer, and hypertension), diseases often associated with particular lifestyles that could not be explained by a single salient causal factor. In this paradigm, the goal of epidemiology was to determine the magnitude and causal nature of the associations between a wide range of putative risk factors and these chronic noncommunicable diseases. This phase began around 1950 and has lasted until current times. (p 1087)

The essential point that Dr. Kendler is making here is that there is a fundamental distinction between these two phases. But is this really so? Let us compare scarlet fever, a classic monocausal infectious disease, with diabetes, which is the first example Dr. Kendler gives of a multicausal chronic disease.

Scarlet fever is caused by a streptococcal infection of the throat, while diabetes is widely considered to arise from many causes, or risk factors, as they are sometimes called. These include inheritance, lifestyle factors, and diet. However, the essential cause of diabetes is an inability of the pancreas to produce enough insulin to adequately process and utilize the sugar in the blood stream. This in turn stems from a damaged or compromised pancreas, ingestion of more sugar than the pancreas can cope with, or other causes. When considered in this light, diabetes is a monocausal illness, even though there are multiple pathways to the final cause.

Applying the same logic in reverse, one can make a case that scarlet fever is multicausal. Firstly, the individuals throat has to be exposed to the streptococcal infection. Secondly, the germ has to survive the initial immune system response. Thirdly, as hand-washing is one of the major protections against contracting this illness, anything that militates against frequent hand-washing could be considered a cause, e.g., living in crowded unsanitary conditions.

In addition, the time period leading up to the contraction of an illness can be analyzed and re-analyzed almost indefinitely. Any incident or event in that time frame has the potential to be considered a contributing cause. Let us say, for instance, that a child contracted scarlet fever at a birthday party given by one of his friends. We could legitimately say that the invitation caused the illness; or that the childs acceptance of the invitation was the cause. Or let us become even more imaginative and say that the child in question was rather shy and didnt want to go to the party, but was prevailed upon by his parents to do so, in the belief that it would do him good. So the illness was caused inadvertently by the parents! And so on.

Back to Dr. Kendlers essay.

During the second half of the 20th century, the approach to disease causation of major parts of psychiatry was out of step with the rest of medicine and medical epidemiology. Instead of multicausal models, the rising and soon to be dominant field of biological psychiatry pursued monocausal models for their major disorders. (p 1088)

The reader will have no difficulty seeing where this is going. Psychiatrists were chasing single causes, for their so-called illnesses, when they should have been looking for many causes. So the great failure of psychiatry to deliver the promised causes wasnt a failure at all. They were simply looking for the wrong kind of explanation. Butand this is the point that Dr. Kendler glosses overit wasnt a benign error. Psychiatry needed clear-cut biological explanations in order to take advantage of the drugs and to establish themselves as bona fide doctors. In this regard they routinely prioritized their own guild interests over the welfare of their clients.

In the early to mid-1960s, through histofluorescence stains, the cell bodies and neuronal pathways of the 3 monoamine neurotransmitters were identified: dopamine, norepinephrine, and serotonin. This further spurred the development of 3 long-lived monocausal neurochemical theories for psychiatric illness. All were proposed in the mid-to-late 1960s: the catecholamine hypothesis of affective disorders, the dopamine hypothesis of schizophrenia, and the serotonin hypothesis of depression. Although based on a range of evidence, the primary support for these theories was reasoning backward from therapeutic mechanisms to etiology. That is, for Parkinson disease the logic was sound: clarification of cause leading to a proposed treatment. By contrast, psychiatry followed the more problematic approach of extrapolating backward from a proposed mechanism of treatment to the cause of the disease. Although the original articles proposing these theories were couched in qualifications, as a psychiatry resident in the late 1970s, I was taught these theories as monocausal explanations. Schizophrenia was caused by excess dopamine transmission. Decades later, I would commonly see patients who would say some version of my psychiatrist said I have a chemical imbalance in my brain and then proceed to summarize one or more of these theories. It is now widely accepted that these theories, claiming a dominant causal pathway to illness, are false although debate continues regarding the dopamine hypothesis. (p 1088) [Emphases added]

Theres a lot in this quote. Firstly, note the phrase Although based on a range of evidence. In fact the evidence supporting these chemical imbalance theories was flawed, i.e. it was not evidence at all. Secondly, note the sentence By contrast, psychiatry followed the more problematic approach of extrapolating backward from a proposed mechanism of treatment to the cause of the disease. [Emphasis added] This was not a more problematic approach; it was a bogus approach; a hoax. And if the psychiatrists who promoted these theories couldnt see the deception, then they had no business presenting themselves as a helping profession. It becameand perhaps still isroutine for mental health workers who drew attention in case conferences to critical psychosocial realities to be told by the psychiatrists that first we have to treat the depression, which invariably meant drugs or electric shocks.

Although the original articles proposing these theories were couched in qualifications, as a psychiatry resident in the late 1970s, I was taught these theories as monocausal explanations. (p 1088)

Dr. Kendler did his psychiatry residence at Yale University, during which, he tells us, he was taught the various chemical imbalance theories, presumably as valid, factual explanations. This seems straightforward enough, and presents no surprises. But there is some ambiguity. If I were to say that my father taught me how to ride a bike, I am actually making two statements. Firstly, I am asserting that my father expended some time and effort in this process, and secondly, that his efforts were successful. In his essay, however, Dr. Kendler leaves this issue vague. Did he believe the hoax, and did he in turn foist it on his customers? It is obvious that Dr. Kendler is a very bright person and, given the fact that the original articles proposing these theories were couched in qualifications, it is reasonable to believe that he did see through the whole sordid deception. So what did he say to the trusting victims who parroted back the bogus theories to him? Did he tell them the truth? Or did he play along?

It is not my intention to pressure Dr. Kendler on this matter. Economics can make cowards of us all. But if he genuinely wants to promote honesty and integrity in this area, it would be helpful if he were to write an expos of sorts concerning the pressures he experienced in these matters during his psychiatric residency at Yale. Such an endeavor would be unlikely to endear him to his colleagues, but would shed light on a facet of psychiatry that has for too long been kept hidden, and might even encourage other psychiatrists to follow suit.

Psychiatry has had a long-term love affair with monocausal theories of illness dating at least from the late 19th century, heavily influenced by our success at the identification and effective eradication of GPI [general paresis of the insane]. In the latter half of the 20th century, with both neurochemical and molecular genetic theories of illness, our enthusiasm for monocausal theories outran our common sense. Emerging from decades of psychoanalytic dominance, we were deeply committed to reestablishing our medical legitimacy. What better way to show that we treated real diseases than to show that they were monocausal? (p 1089)

There is a distinct exculpatory tone to this passage. Instead of acknowledging that psychiatrists were systematically deceiving their customers for their own benefit, Dr. Kendler tells us that it was just a long-term love affair, in which their enthusiasm for monocausal theories outran [their] common sense.

Indeed, as mentioned earlier, this exculpatory stance is one of the dominant themes of the essay. Here are some additional quotes:

Our long yearning for monocausal theories of etiology drives, at least in part, our heartfelt calls for the abandonment of our descriptive nosologic systems in favor of an etiologic model. (p 1089)

There have not been heartfelt calls or long yearning from psychiatry on this matter. Rather, they simply declared the matter resolved, and promoted the chemical imbalance theories as fact. I have written extensively on this subject here.

This search has 2 prominent phases, both fueled by new scientific developments. The first was neurochemical. The stage was set in 1957 by Montagus discovery of dopamine in brain tissue quickly followed, in 1960, by the dramatic finds from Ehringer and Hornykiewicz of the decreased content of dopamine in the postmortem brains of patients with Parkinson disease. Here was a major neurologic disorder fitting apparently into a monocausal neurochemical theory. What could be more exciting for the then young and ambitious field of biological psychiatry? (p 1088) [Emphasis added]

So the systematic, self-serving, and widespread deception perpetrated by psychiatry stemmed from their excitement! How eminently understandable.

The second wave of monocausal theories in psychiatry was genetic. Despite much evidence from family studies that major psychiatric disorders did not segregate in pedigrees as expected for a mendelian condition, the first successful linkage study of Huntington disease in 1983elicited intense excitement in psychiatric genetics and launched a large number of linkage studies, especially of schizophrenia and bipolar illness. (p 1088) [Emphasis added]

Even more excitement!

Yet the ghost of GPIof monocausal psychiatric disorderslurks in our memory. To this day, it influences our nosologic thinking. It makes us too willing to adopt a monocausal perspective in our clinical work and in our explanations of psychiatric disorders to patients. Monocausal thinking continues to support hard reductionist approaches that seek the cause of our major disorders and is one of several factors inhibiting collaborative psychiatric research work across scientific levels. (pp 1089-1090)

So it is the ghost of GPI lurking in psychiatrists collective memories that inhibits them from acknowledging the non-medical nature of depression, painful memories, paranoid thinking, distractibility, etc

Despite the wide acceptance of the chronic noncommunicable disease model in modern medicine, there remains in our culture a sense that disorders with many causes have reduced legitimacy. Therefore, both clinicians and their patients would feel more secure if a large indisputable cause were found for their disorders. This, however, is a social and not a scientific problem. (p 1089-1090) [Emphasis added]

So a monocausal breakthrough would make clinicians and their patients feel more secure. So, telling a bereaved woman that her sadness is the expected and reasonable response to the death of her spouse will make her feel less secure than telling her the gross falsehood that there is something wrong with her brain. Or telling a battered wife that her sadness is the understandable response to the violence would make her feel less secure than telling her it stems from a brain disease. This is exculpation taken to a new level. We lie to our customers because it makes them feel more secure.

Dr. Kendler closes his essay on an upbeat, exhortative note.

The stigma of psychiatric illness and the low status of the psychiatric profession need to be addressed at both social and political levels and will not likely be solved through the discovery of major single causes for our illnesses. The legitimacy of the discipline of psychiatry does not rest on our ability to find single major causes of our disorders. (p 1090)

How does one address the stigma associated with psychiatric disorders and the low status of the psychiatric profession at social and political levels? PR campaigns? Lobbying politicians to pass psychiatry-friendly laws? These things are happening already, but the routine prescribing of pills and electric shocks continues to be psychiatrys only stock in trade, and the self-centered promotion of biological psychiatry continues to dominate the field.

Rather than grieving for the loss of our visions of another GPI around the corner, we can positively embrace the etiologic complexity of our disorders. (p 1090)

Actually they are not psychiatrists disorders. Rather, they are the disorders that psychiatrists self-servingly foist on their hapless clients.

If the common, morbid dysfunctions of the human cardiovascular, immune,hormonal, musculoskeletal, and gastrointestinal systems, which cause most of the morbidity in our country, are highly multifactorial, could we realistically expect anything else from the parallel dysfunctions of our mind/brain system? (p 1090)

In other words, psychiatric illnesses have as much ontological reality as diabetes, heart disease, cancers, hypertension, etc. Dr. Kendler encourages his colleagues not to grieve the abandonment of the quest, but rather to positively embrace the etiological complexity of psychiatric illnesses.

But what does etiologic complexity actually mean in this context, and why is it so important to Dr. Kendler?

Dr. Kendler uses various terms to describe etiologic complexity. For instance, he describes the illnesses in question as multifactorial, chronic noncommunicable, often associated with particular life styles, multicausal, etc.

Dr. Kendler has been working on this general theme for quite some time. In 2012 he published an article in Molecular Psychiatry calledLevels of explanation in psychiatric and substance use disorders: implications for the development of an etiologically based nosology (2012: 17, 11-21). Here are two quotes from the abstract:

The soft medical model for psychiatric illness, which was operationalized in DSM-III, defines psychiatric disorders as syndromes with shared symptoms, signs, course of illness and response to treatment. Many in our field want to move to a hard medical model based on etiological mechanisms. (p 11)

a move toward an etiologically based diagnostic system cannot assume that one level of explanation will stand out as the obvious candidate on which to base the nosology. This leaves two options. Either a hard medical model will be implemented that will require a consensus about a preferred level of explanation which must reflect value judgments as well as science. To take this approach, we need to agree on what we most want from our explanations. Alternatively, we will need to move away from the traditional hard medical model that requires that we ground our diagnoses in single biological essences, and focus instead on fuzzy, cross-level mechanisms, which may more realistically capture the true nature of psychiatric disorders. (p 11)

Theres a lot here. Firstly, there is what many readers might consider a contradiction in the first sentence: The soft medical model for psychiatric illness, which was operationalized in DSM-III, defines psychiatric disorders as syndromes [Emphases added] But syndromes are not illnesses. Heres how DSM-III defines a syndrome:

A grouping of symptoms that occur together and that constitute a recognizable condition. The term syndrome is less specific than disorder or disease. The term disease generally implies a specific etiology or pathophysiological process. In DSM-III most of the disorders are, in fact, syndromes. (p 368)

And elsewhere in the text (p 6), the term mental disorders is defined as a clinically significant behavioral or psychological syndrome. However, even before DSM-III was published (in 1980), it was widely accepted and promoted by psychiatrists that many psychiatric disorders, including depression, were genuine bona fide illnesses. (In my entire career I have encountered only one psychiatrist who acknowledged that psychiatric disorders were syndromes, not real illnesses.) This massive deception has been discussed at great length in various venues and need not be labored here. But what is noteworthy is Dr. Kendlers next sentence: Many in our field want to move to a hard medical model based on etiological mechanisms. But in fact almost all psychiatrists have already made this move and have been promoting the chemical imbalance hoax for decades. Many psychiatrists who are now retired practiced nothing but bio-bio-bio psychiatry for their entire careers.

Obviously Dr. Kendler is aware of this. So, what point is he making?

a move toward an etiologically based diagnostic system cannot assume that one level of explanation will stand out as the obvious candidate on which to base the nosology. (p 11)

In other words: if psychiatrists continue down their present road trying to use science to prove their various disease theories, they are just as likely to discover that major depression, schizophrenia, PTSD, etc., stem from psychosocial and economic causes rather than from their cherished brain diseases. In effect Dr. Kendler is saying: abandon the search or we run the risk of losing everything. (We) cannot assume that one level of explanation will stand out as the obvious candidate on which to base the nosology. In other words, we cannot assume that biological explanations will emerge as the dominant perspective. Dr. Kendler warns his colleagues, we need to agree on what we most want from our explanations. What does he mean by this? Read on.

Here are some quotes from the body of the 2012 article:

Let me sketch what we might find for MD [major depression]. Single gene effects for MD are even smaller and less well established than for AD [alcohol dependence]. Aggregate genetic effects are also somewhat weaker and are modified by a range of environmental exposures. Structural and functional magnetic resonance imaging studies have suggested a range of central nervous system abnormalities that correlate with MD but the specificity and strength of these associations, as well as their causal status, remain uncertain. A number of physiological abnormalities including endocrine and immune function have been reported in cases of MD but again, sensitivity and specificity have typically remained modest. Several aspects of personality are strongly correlated with risk for MDespecially neuroticism. This association is almost certainly causal but is nonspecific as high levels of neuroticism predispose to many internalizing disorders. Some cognitive processes may be more specific and here their causal role has been clearly demonstrated by many randomized controlled trials of cognitive behavior therapy. A range of early environmental risk factors have been well established for MD (for example, poor parenting and sexual abuse) and are generalizable across cultures but are quite nonspecific. Stressful life events can be quite strongly associated with risk for MD. Much, but not all, of this association is likely causal and some classes of events are moderately specific for MD. However, stressful life events are likely to be quite distal influences on risk pathways to MD and many such events predispose to other psychiatric disorders. Economic factors can impact on risk for MD via levels of unemployment and cultural factors can shape the expression and help-seeking behavior of those with depressive syndromes. (p 16)

Nature does not appear to have provided us one critical level of explanation for psychiatric illness that stands out from the background. For CF [cystic fibrosis], explanatory power is highly concentrated in the level of DNA base-pair variation. For psychiatric disorders, explanatory power is dispersed and diffuse. (p 16)

So, genuine scientific investigation might show that depression, say, is as likely to stem from sad events in peoples lives as from any kind of brain disease.

The current status of our science, and, most probably, the nature of psychiatric disorders themselves, does not yield up unambiguous choices for the best level at which to define psychiatric illness etiologically. (p 16) [Emphasis added]

Or might even show that depression is much more likely to stem from sad events.

But, despite these obvious concessions to a bio-psycho-social-cultural-economic perspective, Dr. Kendler is careful not to jettison the baby with the bathwater. He still seeks to preserve the notion that psychiatric disorders are real illnesses.

a rejection of the hard medical model for psychiatric disorders should not be misunderstood as setting up a deep divide between etiologic models for psychiatric and medical disorders. (p 16)

If, as our review of the data suggest, there is no a priori way to pick a single level of explanation on which to base an etiological nosology, we could try to argue it out on pragmatic grounds. What do we most want as a field from our explanations? (p 17)

What indeed? To date, psychiatrys primary motivations have been enhanced prestige, expansion of scope, and increased earning power, all of which were well-served by the chemical imbalance hoax.

What Dr. Kendler is telling his colleagues here is that the hoax is exposed; that science will not give them what they seek; and that by continuing to promote a purely biological perspective they are running the risk of losing what they want most: the reality of psychiatric illness. In other words, the science is not going our way, so we need to ask ourselves what do we most want, and then promote concepts that will help us achieve this. Dr. Kendlers wording is carefully chosen, but it seems to be that he is encouraging his colleagues to dispense with the formalities and neutrality of science and promote concepts that will retain psychiatrys hegemony in the field: what we want most.

Towards the end of the article Dr. Kendler provides us with more descriptors of the psychiatric diagnostic system that he envisions for the future. These include disorders (of) complex, mutually reinforcing networks of causal mechanisms, disordered multi-level mechanisms, and higher-order disturbances in multi-level mechanisms. [Emphases added]

Note the words disorders, disordered, and disturbances. Dr. Kendler, as in the 2019 paper, affords no recognition to the fact that the thoughts, feelings, and actions in question are not actually illnesses, and in many (perhaps most) cases are clearly adaptive.

Four years later (2016) Dr. Kendler published The Nature of Psychiatric Disorders (World Psychiatry, 2016: 15: 5-12). Heres a quote from the abstract:

Therefore, we should argue more confidently for the reality of broader constructs of psychiatric illness rather than our current diagnostic categories, which remain tentative. Finally, instead of thinking that our disorders are true because they correspond to clear entities in the world, we should consider a coherence theory of truth by which disorders become more true when they fit better into what else we know about the world. In our ongoing project to study and justify the nature of psychiatric disorders, we ought to be broadly pragmatic but not lose sight of an underlying commitment, despite the associated difficulties, to the reality of psychiatric illness. (p 5)

Note the phrase we ought to not lose sight of an underlying commitment, despite the associated difficulties, to the reality of psychiatric illness. To which I can only ask: why not? The common and accepted meaning of the word illness is something going significantly awry with the structure or function of an organ. If what psychiatrists call major depression doesnt actually conform to this description, why should psychiatry maintain an underlying commitment to the reality of psychiatric illness? Also, note the phrase In our ongoing project to study and justify the nature of psychiatric disorders [Emphasis added]. Isnt this arguably the very opposite of valid science? Didnt most of the great errors of science stem from efforts to justify the status quo often for the benefit of various powerful conflicting interests?

Despite Dr. Kendlers writings on these matters, his polycausal model is not attracting a large following. Here are quotes from the websites of some psychiatric facilities:

Harvard Medical School: What causes depression?

Certain areas of the brain help regulate mood. Researchers believe that more important than levels of specific brain chemicals nerve cell connections, nerve cell growth, and the functioning of nerve circuits have a major impact on depression. Still, their understanding of the neurological underpinnings of mood is incomplete. [Note how the simplistic chemical imbalance theory is being nudged aside, and being replaced by the more generic notion of nerve functioning.]

This quote is followed by five pages of closely-written type under the following headings: (Brain) regions that affect mood; Areas of the brain affected by depression (with picture); Nerve cell communication; How the (neurological) system works; When the (neurological) system falters; Kinds of neurotransmitters; How neurons communicate (with picture); Genes effect on mood and depression; Temperament shapes behavior; Stressful life events; How stress affects the body; Early losses and trauma; Seasonal affective disorder; Medical problems; and Depression medications.

The material is heavily slanted towards a biological perspective. Even the headings that sound psychosocial are slanted. The section on stressful life events contains:

Disturbances in hormonal systems, therefore, may well affect neurotransmitters, and vice versa.

The section on early losses and trauma contains:

Many researchers believe that early trauma causes subtle changes in brain function that account for symptoms of depression and anxiety. The key brain regions involved in the stress response may be altered at the chemical or cellular level.

Mayo Clinics article Depression (major depressive disorder) under the section Causes:

Its not known exactly what causes depression. As with many mental disorders, a variety of factors may be involved, such as:

Biological differences.People with depression appear to have physical changes in their brains. The significance of these changes is still uncertain, but may eventually help pinpoint causes.

Brain chemistry.Neurotransmitters are naturally occurring brain chemicals that likely play a role in depression. Recent research indicates that changes in the function and effect of these neurotransmitters and how they interact with neurocircuits involved in maintaining mood stability may play a significant role in depression and its treatment.

Hormones.Changes in the bodys balance of hormones may be involved in causing or triggering depression. Hormone changes can result with pregnancy and during the weeks or months after delivery (postpartum) and from thyroid problems, menopause or a number of other conditions.

Inherited traits.Depression is more common in people whose blood relatives also have this condition. Researchers are trying to find genes that may be involved in causing depression.

University of Rochester Medical Center, Major Depression, under the heading What causes depression?

Researchers are studying the causes of depression. Several factors seem to play a role. It may be caused by chemical changes in the brain. It also tends to run in families. Depression can be triggered by life events or certain illnesses. It can also develop without a clear trigger.

And so on. Its clear that most pro-psychiatry writers have received the message to downplay the simplistic too-little-serotonin-in-the-brain theory. Many, however, are still relying on this notion but couching it in different terms or adding some token psychosocial material, usually referred to as triggers.

In psychiatry there is no actual illness behind the symptoms. Major depressive disorder and psychiatrys other functional disorders are nothing more than loose collections of vaguely and arbitrarily defined thoughts, feelings, and behaviors. Psychiatrys clear objective in the past fifty years has been to pathologize every significant difficulty of thinking, feeling, and/or behaving, and to sell these bogus illnesses to the general public, the media, insurance companies, and government officials. The only essential difference between psychiatrists and street-corner drug-pushers is that the latter dont pretend that they are treating or curing illnesses.

Dr. Kendler has written an interesting and thought-provoking essay, but, in my view, has missed the central point: that depression, regardless of severity, duration, or impact, is not an illness. In fact, the opposite is the case. Depression is an adaptive mechanism that encourages us to make changes in our lives, habits, or circumstances. Just as pain provides an incentive to remove our hand from a hot stove, so depression encourages us to leave home, change jobs, develop some assertion skills, find a partner, etc. It is a mechanism that we share with virtually all other animal species, though the precise nature, complexity, and impact of the depression varies enormously.

As a species we can experience a wide range of emotions. We have this ability because we have machinery in our brains, and other organs, that enables this to happen. It is widely believed in psychiatric circles that if neurobiologists could uncover the precise mechanisms involved in experiencing depression, this would prove that depression is an illness. But, in fact, uncovering such mechanisms would no more pathologize depression than the neurobiology of walking or seeing or writing poetry would pathologize these activities. All human activity has a neurobiological underpinning, without which the activity cannot occur. We cannot see without eyes and optic nerves, etc.; we cannot feel without feeling machinery though we dont know exactly what this machinery is or how it works.

It certainly needs to be acknowledged that a persons feeling apparatus can malfunction, but such malfunctions are almost certainly rare, and cannot be routinely inferred from the presence of depression, regardless of severity. I have personally worked with hundreds of depressed individuals in my career, but have never encountered anyone whose level of depression was incommensurate with his/her story. Psychiatrists have essentially numbed themselves to this reality, firstly because of their spurious atheoretical approach (if youve got the symptomsregardless of why youve got themthen you have the illness); and secondly because their primary, or perhaps only, agenda is to clinch the diagnosis. It is particularly interesting in this regard that before the arrival of the pills, psychiatrists, most of whom practiced some kind of psychotherapy, had no difficulty recognizing the reality: that if people are given the opportunity to talk, they can tell you very clearly why they are depressed.

For several decades psychiatry has been lying to its customers that depression is a pathological state caused by a shortage of serotonin, and can, apparently miraculously, be diagnosed without ever examining the brain but simply by scoring yes on five of the nine items on the facile checklist. Some of the more prestigious facilities and colleges are stepping back from the serotonin hypothesis, largely as a result of being outed by the anti-psychiatry movement. But the diagnostic criteria are still the same, and the treatment hasnt changed. Its still eat these pills every day and come back in three months. And if that doesnt work, well try electric shocks.

Sometimes people feel trapped in their circumstances and are unable to muster the resources or skills to effect the necessary changes. An abused wife, for instance, might lack the economic or emotional means to leave her abusive husband. A man stuck in a job that he hates might not be able to see a way out. In cases like these, the depression can appear permanent and unrelenting. What people in these kinds of circumstances need is genuine help to identify the nature of the issues, generate positive targets, and begin the process of change. An abused wife needs a safe home for herself and her children, an effective safety network, and ongoing emotional and practical support. She does not need a diagnosis of major depressive disorder and a bottle of serotonin reuptake inhibitors.

Drugging a perfectly effective depression mechanism out of existence in order to reduce the immediate sense of discomfort and misery is a bit like sticking duct tape over the check engine light on ones dashboard. It may reduce ones negative feelings on the matter, but will produce no lasting benefits. Physicians who participate in these pharma-sponsored activities are not practicing medicine in any true sense of the term. Rather, they are drug pushers, pure and simple.

Dr. Kendler is proposing that psychiatry abandon the search for monocausal explanations of psychiatric illness and embrace the multicausal perspective. His reasoning is that this is a better perspective and is more in tune with present-day approaches to chronic non-communicable illnesses.

But he has perhaps revealed his true motivation in the 2016 paper:

In our ongoing project to study and justify the nature of psychiatric disorders, we ought to be broadly pragmatic but not lose sight of an underlying commitment, despite the associated difficulties, to the reality of psychiatric illness. (p 5)

In this very clear statement, Dr. Kendler is acknowledging an ongoing and underlying commitment to justify psychiatric disorders and to affirm their reality. But isnt this the very antithesis of science? Isnt it a fundamental requirement of science that we leave our beliefsno matter how deeply cherishedat the door, and go where the science takes us? How much credence should we afford a scholar who acknowledges, apparently without compunction, that in his work and writings his agenda includes an underlying commitment to the reality of psychiatric illness?

Read more from the original source:
The Chemical Imbalance Theory of Depression: Where Is It Going? - James Moore

Read More...

Using isotopes to reconstruct life histories within the transatlantic slave trade – UC Santa Cruz

Tuesday, February 18th, 2020

"We know villages were destroyed and people were being taken," says Vicky Oelze. "We want to put numbers on it. I'm interested in individual histories." (Photo by Fred Deakin)

This geological map of equatorial Africa shows strontium isotope sampling locations Oelze's team will use to create the first-ever strontium isotope map of the region, a tool researchers will use to help trace the origins of Africans who were abducted during the transatlantic slave trade. (Map courtesy of Vicky Oelze)

Vicky Oelze, an assistant professor of anthropology, should introduce herself as a detective. Who else would attempt to fill in the gaps of the transatlantic slave trade by gathering clues from cemeteries in South Carolina and the shores of West Africa?

Four hundred years after the forced displacement of millions of Africans began, Oelze wants to use isotope biogeochemistry to trace back and identify the origins of individuals who were abducted and perished in the Americas.

Skeletal remains of slaves hold the clues that Oelze will use to identify where in Africa individuals were born and raisedinformation that has been lost to history.

"The narrative we have now is based on log books written by people who were deporting hundreds of Africans on ships," said Oelze. "They documented only the numbershow many left and how many arrived in the respective harbors. There was no recordkeeping of where people were actually from."

Archaeologists have had great success in parts of the developed Western world using strontium isotopes to identify the geological origin of prehistoric people, matching data to detailed strontium isotope maps researchers have developed. This type of map does not exist for tropical Africa, a gap Oelze will fill with over 400 environmental samples from 40 field sites that cover most major geological formations in tropical Africa. The principle is simple: Vegetation takes up a specific isotopic makeup of the trace element strontium from bedrock, and, in tiny quantities, that isotopic "signature" becomes locked in the teeth of people and animals that consume it. Oelze will use samples of African flora and fauna to build a strontium isotope map to match the signatures in skeletal remains of slaves to specific regions in Africa.

With support from the Helen and Will Webster Foundation, Oelze is hiring a postdoctoral researcher for two years to work in partnership with collaborators at the Max Planck Institute for Evolutionary Anthropology in Germany. In a second step, the team will start examining human remains from the Americas for their strontium isotope values. Strontium isotope analysis is particularly valuable when deterioration of skeletal material has ruled out genetic analyses as an option, and it is a much more precise way to assess human mobility on an individual, rather than population, level, said Oelze. The team will also analyze human remains from urban centers of the West African slave trade in collaboration with UCSC archaeologist Cameron Monroe.

"We know villages were destroyed and people were being taken," said Oelze. "We want to put numbers on it. I'm interested in individual histories."

The remains of millions of slaves are buried in designated slave cemeteries and near slave trade centers in the Caribbean and the Americas, as well as in informal burial plots that have been lost to history, noted Oelze. "It is imperative to include descendant communities in the process, she said. Many have a genuine interest in their ancestors. It's important to them, which is why so many are turning to 23andMe."

However, genetics from Africa are postcolonial and therefore flawed, said Oelze. As people were displaced by the pressures of slave raids, they effectively erased their geographic origins; strontium isotope analysis holds the promise of retracing movements from the past, she said.

Oelze's results will also aid wildlife conservation. "Trafficking of endangered animals is of growing concern to conservation, and this map of strontium isotopes in tropical Africa will help identify hotspots of illegal poaching activity," said Oelze, who plans to share her data internationally in open-access publications. She is also eager to use the findings to spark interest in STEM fields among students from Historically Black Colleges and from high schools with diverse student populations.

A hub of excellence

UC Santa Cruz has the potential to lead the field in tracing the histories, geographies, and molecular archaeology of the slave trade, according to Katharyne Mitchell, dean of the Division of Social Sciences. In Anthropology, Lars Fehren-Schmitz brings expertise in the analysis of ancient DNA, and Monroe has conducted extensive research in Bnin and Togo on the transformation of West African communities during the slave trade, as well as related archaeological research in the Caribbean. In History, Professor Greg O'Malley has done pathbreaking work on the transatlantic slave trade.

"This cohort of brilliant scholars is doing transformational work," said Mitchell. "Vicky is a powerhouse, and I'm delighted the Webster family wanted to support her research. I see great things emerging from this."

Oelze, who joined the faculty in 2016 from the Max Planck Institute for Evolutionary Anthropology, will organize a symposium on campus on the molecular forensics of the transatlantic slave trade, drawing historians, archaeologists, isotope geochemists, and geneticists to campus.

Read this article:
Using isotopes to reconstruct life histories within the transatlantic slave trade - UC Santa Cruz

Read More...

Consumer DNA testing is a bust: Here’s how companies like Ancestry and 23andMe can survive – CNBC

Monday, February 10th, 2020

A reporter examines a 23andMe DNA genetic testing kit in Oakland, California.

Cayce Clifford | Bloomberg | Getty Images

It has not been a good year for consumer DNA testing companies.

In January, Silicon Valley-based 23andMe laid off 100 employees, about 14% of its workforce. A month later, Ancestry, which has offices in Utah and San Francisco, also cut 100 jobs, representing about 6% of its staff.

The major reason for the downsizing? Simply put, consumers aren't buying as many at-home DNA tests as they used to.

The first sign came in the summer, when Illumina, maker of the DNA sequencing machines that are used by Ancestry and 23andMe, acknowledged in an earnings call to investors that the category had hit a lull. CEO Francis DeSouza didn't share an explanation for that, but noted that Illumina was taking a "cautious view" of the opportunity in the near term. Orasure, maker of the spit tubes used by consumer DNA testing companies, has also seen its stock take a hit.

At that time, some smaller companies were already feeling the impact. Helix, a start-up that spun out of Illumina to build an "app store" model for DNA tests, cut staff in May. The company revealed to Bloomberg that it was shifting its focus away from consumers to population health, meaning it would work with health industry partners. A few months later, Veritas Genetics another company focused on consumers that sold more expensive but more detailed whole genome sequencing tests shuttered its U.S. operations.

So what happened? There hasn't yet been a detailed study to understand the shift in consumer thinking around these tests. But CNBC spoke with some of the leading genetics experts and doctors, who shared a few theories.

Dawn Barry, a former Illumina executive with a start-up in the space called LunaDNA, blames a few factors, especially privacy concerns.

Consumers have seen a slew of reports in the past few years about how companies are using their personal data for targeted advertising, without their knowledge, and might be feeling particularly sensitive about their health information.

Anne Wojcicki, CEO of 23andMe, has previously referred to these concerns as the "Facebook effect." In her view, consumers are increasingly freaked out about stories they're reading in the media about privacy, mostly about Facebook and other technology companies, and are reacting by feeling anxious about getting DNA tests.

Companies like 23andMe do make money off this information. Her company does ask for consent from users and it has publicly explained its revenue model, but a big part of its business involves its relationships with pharmaceutical companies like GlaxoSmithKline. 23andMe also has a therapeutics arm, where it is hoping to leverage its database of millions of people's DNA to develop new drugs.

Making matters worse for these companies, suggests Barry, is the Golden State Killer case. Law enforcement honed in on a suspect after running DNA from a decades-old crime scene through a free online database, where anyone can upload their genetic information.

A suspect was found through a distant relative who might have paid for a test via Ancestry or 23andMe, and then uploaded it into the database.

The case raised all sorts of complicated questions about whether genetic information is fundamentally different than other types of data because it implicates family members and not just individuals.

Other experts suspect that consumer DNA testing companies might have run out of early adopters. The theory goes that there's about 20 million or 30 million consumers who are naturally interested in learning more about their family background, and it's not that challenging or expensive to sell tests to them. At this point, many of these people have already been sold to, and there's no reason for them to buy a second test. Ancestry has sold about 14 million tests, and 23andMe has sold some 9 million.

But many people are wary about learning information they might not want to know like the father who raised them isn't their biological father or that they have a risk for a genetic disease that they can't take a pill to prevent.

There's likely a larger consumer segment that's interested, but still wary about these tests. They might not believe that the information is valuable enough to warrant the price tag. The cheapest tests sell for $99, and they'll cover ancestry and some health risks but lack truly actionable health information, like whether an individual might respond poorly to a drug based on their genetic makeup.

"The ancestry market is a finite market," said David Mittelman, CEO of Othram, a genomics start-up and a molecular physicist. A decade or so in, "these companies are beginning to tap out the market."

Mittelman notes that customer acquisition costs, including ad dollars these companies need to spend on sites like Facebook, will increase over time.

"I think the companies know this," he said. "The investment in health shows that they are working to appeal to a broader market."

What's noteworthy about the recent round of layoffs is that Ancestry kept all of its employees at its Ancestry Health business. And 23andMe is still highly focused on its drug development business. That suggests that both companies are indeed hinging their future on developing powerful health applications.

In light of that, some geneticists are optimistic about their future.

"First of all, a slowdown isn't a stoppage," said Dr. Robert Green, a professor of genetics at Harvard Medical School. "Our research is finding that genetics is about to take its rightful place in medical care for the world."

As Green explains, it's been a challenge for doctors to understand how genetics can inform their patient care. Many haven't had the education about genetics to understand how to talk about it with their patients or recommend tests that might be beneficial. But that's starting to change.

For instance, 23andMe is starting to roll out new tests that can identify people's risk for chronic diseases like diabetes, called polygenic risk scores. These results could be used by doctors to help steer their patients toward making healthier lifestyle choices to help them avoid getting the disease.

And for these companies, which already have genetic databases of millions of people, they might not need to keep spending ample marketing dollars to acquire new customers. Instead, they could focus on developing new insights from their existing databases. if they succeed at that, they can forge partnerships to the medical industry.

As Mittelman puts it, there's no need to "force people down an ancestry funnel."

Green agrees, saying companies like 23andMe and Ancestry might double down on more expensive but more detailed sequencing tests that provide a lot more relevant health information. 23andMe has dabbled with those kinds of tests but has been reluctant to roll out higher-priced tests while its main focus has been growth.

"The direct-to-consumer phenomenon will give way to a more of a proper integration of genomics into the day-to-day care of patients," said Green. "What we're seeing is a course correction, and consumers are waking up to the potential limitations of a $99 test."

CNBC Evolve will return, this time to Los Angeles, on June 8. Visit cnbcevents.com/evolve to apply to attend.

Read this article:
Consumer DNA testing is a bust: Here's how companies like Ancestry and 23andMe can survive - CNBC

Read More...

Page 21«..10..20212223..30..»


2024 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick